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The function of the Heg-CCM pathway in zebrafish heart development 
Abstract 
 
  The Heart of glass-Cerebral Cavernous Malformation (Heg-CCM) pathway is essential 
for heart development in zebrafish and mouse.  In zebrafish, mutants for the Heg-CCM genes 
ccm1, ccm2, and heg exhibit an extreme dilation of the heart chambers and inflow tract and 
completely lack blood circulation.  The mechanisms by which this pathway regulates heart 
development are incompletely understood.  Two major impediments to our knowledge are the 
paucity of genes known to participate in the Heg-CCM pathway and a lack of information about 
how the Heg-CCM pathway interacts with other signaling pathways in live embryos. 
  To address the first hurdle, we have undertaken two approaches.  First, we performed a 
yeast 2-hybrid screen to identify proteins that interact with Heg, the transmembrane protein 
component of the Heg-CCM pathway.  We find that zebrafish Heg interacts with Ccm1, which is 
consistent with others’ findings about the mouse orthologs of these proteins, suggesting that the 
Heg-Ccm1 interaction is conserved across vertebrate species.  Second, we employed a 
bioinformatic approach to identify novel proteins bearing high sequence identity to the known 
Heg-CCM pathway components.  Using this strategy, we discovered the novel protein Ccm2-like 
(Ccm2l) and performed analyses of Ccm2l in zebrafish and cell culture.  We found that loss of 
ccm2l causes the heart’s atrium to dilate and that this phenotype can be partially rescued by 
overexpression of ccm2.  Slight knockdown of ccm2l can enhance the heart phenotype in 
embryos sensitized by a low dose of morpholino against ccm1, and Ccm2l protein can bind iv 
 
Ccm1 protein in an overexpression system.  Taken together, we conclude that ccm2l is required 
for normal heart development as a component of the Heg-CCM pathway. 
  To address the second hurdle, we focus on the interactions between the Heg-CCM 
pathway and the extracellular signal-regulated kinase (Erk) pathway in the zebrafish heart.  We 
find that global inhibition of Erk causes dilation of the atrium, while myocardial hyperactivation 
of Erk results in a shrunken heart.  Moreover, global hyperactivation of Erk can partially rescue 
heg morphant phenotypes.  We propose a model in which one function of the Heg-CCM pathway 
is to regulate Erk activity in the developing myocardium. 
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Chapter 1: An introduction to zebrafish heart development and the 
Heg-CCM pathway 
   2 
 
Zebrafish as a model for cardiovascular development 
 
  The zebrafish Danio rerio offers many advantages as a model for vertebrate 
development.  First, zebrafish are fecund; a single mating pair can produce hundreds of fertilized 
eggs in a single morning.  Second, fertilized eggs simply sink to the bottom of the breeding cage, 
making it trivially easy to obtain them.  Third, zebrafish embryos develop externally and are 
transparent, allowing for direct visualization of morphogenesis throughout embryonic 
development.  Fourth, zebrafish development is extremely rapid, with the progression from 
fertilized egg to free-living larva taking just 5 days.  Fifth, zebrafish are amenable to increasingly 
sophisticated genetic manipulations, including forward genetics by mutagenesis screening, 
reverse genetics by targeted morpholino knockdown or TALEN knockout, and the generation of 
transgenic animals in which integrated genes are expressed with temporal or spatial specificity. 
The zebrafish has been used extensively to study the development of many organs, 
including the heart, the first functional organ to form in the animal.  The zebrafish heart has only 
two chambers: one atrium and one ventricle (Figure 1.1A).  However, its function and 
development are similar to its mammalian counterparts’.  The embryonic zebrafish heart contains 
two tissues: the endocardium and the myocardium (Figure 1.1B).  The endocardium is a 
specialized endothelium lining the inside of the heart that is continuous with the rest of the 
animal’s vasculature.  The myocardium is the heart’s muscle which contracts rhythmically to 
generate blood circulation. 3 
 
 
Figure 1.1.  Structure of the embryonic zebrafish heart.  (A) A fixed 48 hpf zebrafish embryo 
subjected to in situ hybridization and antibody staining using chamber-specific markers.  The 
view is ventral with anterior at the top. a, atrium, v, ventricle.  Figure 1.1A is taken from Mably 
et al., 2006.  (B) Schematic depicting a cross section cut through a 48 hpf ventricle.  The 
myocardium is red and the endocardium is blue. 
 
It is an ongoing challenge for developmental biologists to decipher the steps that lead to 
the generation of a heart, and the strengths of the zebrafish system have made it immensely 
valuable in pursuing this goal.  Owing largely to the embryo’s transparency, as well as the use of 
transgenic zebrafish lines in which specific cell populations are labeled with fluorescent 
reporters, we have a detailed understanding of the morphological events required to generate a 
mature heart (Stainier, 2001).  During somitogenesis, partially differentiated heart cells migrate 
from the left and right lateral plate mesoderm toward the midline.  At the midline, the two 
converging populations form a structure called the cardiac cone, which then extends into the 
primitive heart tube.  Around this time, a mere 22-24 hours post fertilization (hpf), the heart 
begins to beat.  Even so, further morphological events are required to generate a mature heart.  
By 36 hpf, a process termed looping occurs, in which the ventricle is placed to the right of the 4 
 
midline, and the atrium to the left.  Endocardial cushions, the precursors to valves, form, and an 
extracellular matrix called cardiac jelly forms between the endocardium and the myocardium. 
These morphological events are under genetic control, and zebrafish mutants isolated 
from mutagenesis screens have been indispensable in identifying and characterizing the relevant 
genes and pathways.  One example of a mutant that led to unexpected discoveries about heart 
morphogenesis is miles apart (mil).  In mil mutants, the bilateral populations of cardiac 
precursors fail to migrate to the midline.  Positional cloning revealed that the mil gene encodes a 
sphingosine-1 phosphate receptor, leading to the discovery that lysosphingolipid signaling is 
required for heart fusion (Kupperman et al., 2000).  Lysosphingolipids had been known to 
function in other contexts, but until the characterization of mil it was unknown that they play a 
crucial role in heart development. 
 
ccm1, ccm2, and heg are part of a signaling pathway that is required for cardiovascular 
development 
 
  In the treasury of zebrafish mutants, none have heart phenotypes more striking than santa 
(san), valentine (vtn), and heart of glass (heg).  In these mutants, early morphogenic processes 
such as precursor migration and fusion occur normally.  The first signs that heart development is 
perturbed appear around 28 hpf, at which time wildtype embryos have visible blood circulation 
but the mutants do not.  By 48 hpf, the mutant hearts and inflow tracts are massively dilated 
(Figure 1.2A).  Mutant hearts beat, but there is no circulation of blood cells.  By 72 hpf, the 
ventricular myocardium is 2-3 myocytes thick in wildtype embryos, but in mutants it remains a 
single cell layer (Mably et al., 2003).  Surprisingly, the number of myocardial and endocardial 5 
 
cells in these mutants is the same as in wildtype embryos; thus, the extreme increase in the size 
of the heart chambers is accomplished without cellular hyperproliferation (Mably et al., 2006; 
Mably et al., 2003).  While the dilated heart is the most conspicuous phenotype in san, vtn, and 
heg mutants, other endothelial vessels are also affected, as  san and vtn mutants have been shown 
to exhibit dilation of the subintestinal vein (SIV) and posterior cardinal vein (PCV) (Hogan et al., 
2008).   The animals die around 5 days post fertilization (dpf), which is typical for zebrafish 
embryos with any sort of severely impaired cardiovascular development. 
   6 
 
 
 
Figure 1.2.  The Heg-CCM pathway is required for normal heart development.  (A) In 
wildtype embryos at 48 hpf, the chambers of the heart are compact and the inflow tract is 
narrow.  In heg mutants at 48 hpf, the heart chambers and inflow tract are massively dilated.  san 
and vtn mutants have heart phenotypes nearly indistinguishable from heg. a, atrium; it, inflow 
tract; v, ventricle.  Images taken from Mably et al., 2003.  (B) Schematic showing the Heg-
Ccm1-Ccm2 complex.  Heg is a single-pass transmembrane protein whose intracellular domain 
binds Ccm1.  Ccm1 binds numerous other proteins, including the cytoplasmic protein Ccm2.  
This schematic applies to both zebrafish and mammals. 
 
The genes disrupted in the san, vtn, and heg mutants are named cerebral cavernous 
malformation 1 (ccm1), cerebral cavernous malformation 2 (ccm2), and heg, respectively.  All 
three genes are conserved across vertebrate species and are also required for cardiovascular 
development in mouse.  (See Table 1.1.)  Genetic deletion of murine Ccm1 confers numerous 7 
 
cardiovascular defects in the developing embryo.  The heart’s atrium is enlarged and there are 
pericardial effusions.  The aorta and intersomitic arteries are enlarged as well, and staining for 
the arterial marker Efnb2 reveals a loss of arterial identity (Whitehead et al., 2004).  When Ccm2 
is knocked out in the mouse instead, embryos also exhibit pericardial effusions.  The branchial 
arch arteries fail to lumenize, and different regions of the aorta are either constricted or enlarged 
(Boulday et al., 2009; Whitehead et al., 2009).  When Heg1, the mouse homolog of heg, is 
knocked out, embryos exhibit pulmonary hemorrhage, blood-filled pericardial sacs, and dilated 
lymphatic vessels.  Additionally, in histological sections, the ventricle has a “honeycombed” 
appearance owing to the invagination of the heart cavity into the myocardium (Kleaveland et al., 
2009).  Ccm1 and Ccm2 knockouts die in utero, while half of all embryos null for Heg1 survive 
until birth (Boulday et al., 2009; Kleaveland et al., 2009; Whitehead et al., 2009; Whitehead et 
al., 2004). 
   8 
 
Table 1.1.  Nomenclature for genes in the Heg-CCM pathway.  For historical reasons, Ccm1, 
Ccm2 and Ccm3 each have multiple names.  (Ccm1: Krev interaction trapped gene 1. Ccm2: 
Malcavernin, Osmosensing scaffold for mekk3. Ccm3: Programmed cell death 10.)  For clarity, 
in this dissertation we use only the gene names presented in this table, with the established 
species-specific nomenclature. 
 
 
Zebrafish gene  ccm1  ccm2  heg  ccm3a and ccm3b 
Zebrafish mutant  san  vtn  heg  N.A. 
Zebrafish protein  Ccm1  Ccm2  Heg  Ccm3a and Ccm3b 
Mouse gene  Ccm1  Ccm2  Heg1  Ccm3 
Mouse protein  Ccm1  Ccm2  Heg1  Ccm3 
Human gene  CCM1  CCM2  HEG1  CCM3 
Human protein  CCM1  CCM2  HEG1  CCM3 
 
 
   
In contrast to mouse, where the Heg1 knockout is quite distinct from the Ccm1 and Ccm2 
knockouts, in zebrafish all three mutants have essentially the same phenotype: a massively 
dilated heart and no circulation of blood cells.  Moreover, this phenotype has not been observed 
in any other mutants.  These observations suggest that ccm1, ccm2, and heg may operate in a 
common pathway in zebrafish.  In a test of this hypothesis, it was found that slight knockdown of 
any of the three genes by morpholino injection can drastically enhance heart phenotypes in 
embryos sensitized by a subphenotypic dose of morpholino against either of the other two 
(Mably et al., 2006).  Similarly, in mouse, Heg1 knockout phenotypes are enhanced in animals 9 
 
haploinsufficient for Ccm2; approximately half of Heg1
-/-;Ccm2
+/+ embryos survive to birth, but 
all Heg1
-/-;Ccm2
+/lacZ embryos die in utero (Kleaveland et al., 2009).  Thus, in both zebrafish and 
mouse, ccm1, ccm2 and heg interact genetically; they are core components of what is called the 
Heg-CCM pathway. 
ccm1, ccm2, and heg and their murine counterparts are all expressed in multiple tissues, 
making it nontrivial to ascertain which tissue the Heg-CCM pathway is required in for normal 
development to occur.  Fortunately, a breakthrough occurred several years ago, when two groups 
found that the phenotypes in the Ccm2 null mouse are recapitulated in mice in which Ccm2 is 
selectively deleted from the developing endothelium.  These findings strongly suggest that the 
Heg-CCM pathway’s activity is required in the endothelium (Boulday et al., 2009; Whitehead et 
al., 2009).  in situ hybridization experiments in zebrafish embryos detect heg RNA in the 
endocardium but not the myocardium, consistent with a model in which Heg-CCM signaling in 
the heart’s endothelium regulates heart morphology (Mably et al., 2003). 
The genetic interactions among ccm1, ccm2, and heg are nicely complemented by 
biochemical evidence showing that the proteins encoded by these genes form a complex (Figure 
1.2B).  Ccm1 is a large cytoplasmic/nuclear protein containing three NPXY/F motifs, ankyrin 
repeats, and a band 4.1/ezrin/radixin/moesin (FERM) domain.  In general, ankyrin repeats are 
thought to mediate protein-protein interactions, though the function of Ccm1’s ankryrin repeats 
in unknown.  FERM domains localize cytoplasmic proteins to the plasma membrane.  Ccm2 is a 
smaller cytoplasmic protein.  Its only domain or motif recognizable by primary amino acid 
sequence is a phosphotyrosine binding (PTB) domain at its N-terminal end.  Co-
immunoprecipitation, fluorescence resonance energy transfer (FRET), and yeast 2-hybrid 
experiments have demonstrated physical interactions between human CCM1 and CCM2 10 
 
(Zawistowski et al., 2005; Zhang et al., 2007).  Heg is a single pass transmembrane protein with 
epidermal growth factor (EGF)-like repeats in its extracellular domain.  The intracellular domain 
of Heg is the most highly conserved part of the protein, and it binds the Ccm1-Ccm2 complex 
through Ccm1.  This interaction was demonstrated by others for mammalian proteins 
(Kleaveland et al., 2009) and in this dissertation (Chapters 2 and 3) for the zebrafish orthologs.   
Ccm1-Ccm2 binding involves an interaction between the NPXY/F motifs of Ccm1 and 
the PTB domain of Ccm2.  A point mutation that disrupts the PTB domain of CCM2 abolishes 
CCM1-CCM2 binding (Zawistowski et al., 2005).  There is mixed evidence in the literature on 
the contributions of the individual NPXY/F motifs of CCM1 to the CCM1-CCM2 interaction.  
One group found that the first NPXY/F motif of human CCM1 is dispensable for binding to 
CCM2 but that binding could be impaired by mutagenesis of the second and third NPXY/F 
motifs (Zhang et al., 2007).  A different group found that mutagenesis of the first NPXY/F motif 
subtly reduced the strength of the CCM1-CCM2 interaction but did not detect any changes in 
CCM1-CCM2 binding upon disruption of the second or third NPXY/F motifs (Zawistowski et 
al., 2005).  These disparate results are probably due to the groups’ different strategies for 
disrupting the NPXY/F motifs and their different assays in measuring binding strength. 
In human and mouse CCM1, there is one NPXY motif followed by two NPXF motifs.  
NPXY and NPXF motifs are structurally similar, but because tyrosine and not phenylalanine is a 
substrate for cellular kinases, typically only NPXY motifs are subject to regulation by 
phosphorylation.  Interestingly, the second NPXF motif contains a tyrosine in the third position, 
and a recent mass spectrometry study found that this residue is phosphorylated while the tyrosine 
in the NPXY motif is not (Kim et al., 2011).  The functional significance of this unusual NPXF 
phosphorylation event is unknown. 11 
 
 
 
Cellular functions of the Heg-CCM pathway 
 
  In the last several years there have been numerous studies elucidating the cellular 
functions of the Heg-CCM pathway.  Ccm2 was originally discovered by a yeast 2-hybrid screen 
using the kinase MEKK3 as bait.  MEKK3 is a component of the p38 pathway, which is 
activated in response to hyperosmolarity and other cellular stresses.  siRNA-mediated 
knockdown of CCM2 in cell culture inhibits the activation of p38 in response to hyperosmotic 
shock; thus, CCM2 is a necessary component of the p38 pathway (Uhlik et al., 2003).  This role 
for Ccm2 was validated by another group using mouse embryonic fibroblasts (MEFs) 
heterozygous for Ccm2 (Zawistowski et al., 2005). 
It is not easy to explain why attenuation of the p38 stress response pathway would cause 
the heart and vascular defects observed in Heg-CCM mutant animals.  There are, however, other 
pathways affected by Heg-CCM gene perturbation that have the potential to at least partially 
explain the mutant phenotypes observed in zebrafish and mouse.  Chief among them is the RhoA 
pathway. 
RhoA is a small GTPase that promotes stress fiber formation and tissue permeability in 
endothelial cells.  Like all GTPases, RhoA cycles between an active GTP-bound state and an 
inactive GDP-bound state.  GTP-bound RhoA activates its effector molecule Rho-associated 
Protein Kinase (ROCK), which phosphorylates myosin light chain phosphatase (MLCP), 
preventing MLCP from deactivating (via dephosphorylation) myosin light chain (MLC).  12 
 
Phosphorylated MLC promotes the formation of stress fibers and reduces cell adhesion by 
disrupting adherens junctions, causing tissue permeability (Spindler et al., 2010). 
  The link between Heg-CCM signaling and RhoA was identified on the basis of the 
phenotype observed in endothelial cells depleted of CCM1 or CCM2 by siRNA.  Staining of 
actin in these cells shows increased stress fiber formation and monolayer permeability assays 
show decreased barrier function (Glading et al., 2007; Stockton et al., 2010; Whitehead et al., 
2009).  As these phenotypes predict, knockdown of CCM1 or CCM2 causes an increase in 
cellular levels of activated RhoA (Borikova et al., 2010; Crose et al., 2009; Stockton et al., 2010; 
Whitehead et al., 2009).  The Heg-CCM pathway also appears to regulate RhoA in vessels in 
mouse, as Ccm2
+/- adult mice exhibit a vascular leakiness phenotype that can be suppressed by 
administration of drugs that target the RhoA pathway (Stockton et al., 2010; Whitehead et al., 
2009). 
  To repress the RhoA pathway, CCM proteins must reach the cell junction where RhoA is 
active and then somehow constrain its activity.  The means by which Ccm1 arrives at the cell 
junction are becoming clear.  Recent studies show that CCM1 normally resides on microtubules 
but is recruited to cell junctions by the small GTPase Rap1 (Glading et al., 2007; Liu et al., 
2011).  At the cell junction, it binds proteins associated with adherens junctions, including β-
Catenin and p120, through its FERM domain (Glading et al., 2007).  Endogenous CCM2 
(Stockton et al., 2010) and overexpressed Heg1 (Kleaveland et al., 2009) both reside at cell 
junctions, and both are required to localize CCM1 there (Gingras et al., 2012; Stockton et al., 
2010).  How the Heg-CCM complex inhibits RhoA after it is assembled at the cell junction is 
unclear.  It has been found in an overexpression system that CCM2 co-immunoprecipitates with 
RHOA (Whitehead et al., 2009), so the mechanism may be direct.  One group has found that 13 
 
CCM2 promotes the degradation of RHOA protein by recruiting the E3 ubiquitin ligase 
SMURF1 to the membrane (Borikova et al., 2010; Crose et al., 2009).  However, in other 
studies, total RHOA levels were unaffected by depletion of CCM1 and CCM2 (Stockton et al., 
2010; Whitehead et al., 2009).  More research will have to be done to resolve the mechanism by 
which the Heg-CCM pathway restricts RhoA signaling.  
Can the cardiovascular phenotypes in embryos homozygous mutant for Heg-CCM 
pathway genes be explained by RhoA hyperactivation and loss of adherens junctions?  In both 
mouse and zebrafish, there is evidence of altered endothelial cell junctions.  In the Heg1 
knockout mouse, mesenteric lymphatic vessels exhibit shortened endothelial junctions, as 
assayed by electron microscopy. In ccm2 morphant zebrafish embryos, the junctions between 
endocardial cells are shortened as well (Kleaveland et al., 2009).  It is relatively easy to explain 
the Heg1 mouse knockout phenotypes by a reduction in endothelial junction length, since 
knockouts have defects in vascular integrity (Kleaveland et al., 2009).  However, in zebrafish, 
where the most profound Heg-CCM mutant phenotype is the massively dilated heart (Mably et 
al., 2006; Mably et al., 2003), it is more challenging to attribute the Heg-CCM loss-of-function 
phenotype entirely to a loss of adherens junctions.  While the shortened junctions between 
endocardial cells would result in less overlap between adjoining cells and expansion of the 
tissue’s surface area (Figure 1.3A), it is not clear that this process would be sufficient to explain 
the massive increase in organ size. 14 
 
 
Figure 1.3.  Two models for the enlargement of heart chambers in Heg-CCM pathway 
mutants.  (A) vtn mutants have reduced areas of overlap between adjoining endocardial cells 
(Kleaveland et al., 2009).  Even if endocardial cells are the same size in vtn mutants, this 
reduction in overlap would cause an expansion of the heart chamber’s surface area.  (B) An 
increase in endocardial cell size in Heg-CCM pathway mutants could also contribute to an 
increase in heart chamber size.  Cell-cell interfaces are marked in red.  Arrows show lumen 
diameter.  For clarity, myocardium is not pictured. 
 
In addition to altered cell junctions, changes in cell shape and size may also contribute to 
cardiovascular defects in san, vtn, and heg mutants (Figure 1.3B).  Cell shape has been examined 
in detail in the PCV in zebrafish, and it was found that wildtype endothelial cells in this tissue 
have an elongated morphology, whereas san mutant endothelial cells are rounder and spread out 
with more surface area; furthermore, zebrafish transplantation experiments showed that this 
function of ccm1 in controlling cell shape is cell autonomous.  In this study, surprisingly, no 
differences in cell junctions were detected between wildtype and san embryos (Hogan et al., 15 
 
2008).  Clearly, more research will be required to ascertain how cell junctions, cell shape, and 
possibly other factors contribute to the morphological defects observed in mutants of the Heg-
CCM pathway. 
In addition to the p38 stress response pathway and RhoA signaling, several other 
pathways have been shown to be affected by loss or gain of Heg-CCM gene activity.  For 
example, one study shows that overexpression of CCM1 in human umbilical vein endothelial 
cells (HUVECs) reduces activation of ERK and increases activation of AKT and Notch 
(Wustehube et al., 2010).  (We explore the relationship between ERK and the Heg-CCM 
pathway in Chapter 4 of this dissertation.)  Another study shows that loss of Ccm2 leads to 
hyperactivation of the c-Jun NH2-terminal protein kinase (JNK) pathway (Whitehead et al., 
2009).  Given the number of important pathways affected by manipulation of genes in the Heg-
CCM pathway, it may be the case that the cardiovascular defects found in homozygous mutant 
fish and knockout mice are due not to a single misregulated pathway, but rather to the 
cumulative effects of many misregulated pathways. 
 
Mutations in CCM1 and CCM2 cause cerebral cavernous malformations in humans 
 
  The genes ccm1 and ccm2 owe their names to the finding that mutations in their human 
orthologs cause vascular pathologies known as cerebral cavernous malformations (CCMs).  
CCMs are dilations of the vascular endothelium of the brain.  Histologically, CCM lesions have 
a thin-walled endothelial lining and lack smooth muscle and elastic tissue.  While some CCM 
lesions are asymptomatic, others cause devastating symptoms including severe headaches, 
seizures, focal neurological deficits, and even death.  Typically, CCM patients first present as 16 
 
adults.  CCMs can be either familial or sporadic and affect approximately 0.5% of the population 
(Cavalcanti et al., 2012).  Mutations in three genes have been shown to cause CCM disease: 
CCM1 (Laberge-le Couteulx et al., 1999; Sahoo et al., 1999), CCM2 (Denier et al., 2004; Liquori 
et al., 2003), and CCM3 (Bergametti et al., 2005).  The majority of CCM patients have mutations 
in CCM1; one study found that in a cohort of patients, 53% had mutations in CCM1, 15% had 
mutations in CCM2, and 10% had mutations in CCM3 (Denier et al., 2006).  For all three genes, 
inheritance of the disease follows an autosomal dominant pattern.   
It is thought that familial CCM disease is caused by loss-of-function of the genes CCM1-
3.  Evidence for this hypothesis includes the finding that the majority of mutant alleles for all 
three genes contain premature stop codons, which can lead to either nonsense mediated decay of 
the mRNA or a truncated protein (Cave-Riant et al., 2002).  Additionally, immunohistochemistry 
shows that each CCM protein is undetectable in the lesions of patients bearing mutations in that 
gene; for example, in a patient heterozygous for a mutant CCM1 allele, CCM1 protein is 
detectable in normal tissue but not in the CCM lesion (Pagenstecher et al., 2009).  Presumably, 
the extreme reduction or complete absence of the protein causes a loss-of-function phenotype. 
Why do patients with germline mutations in CCM1-3 develop CCM disease relatively 
late in life?  And why, if all the cells in the body harbor the germline mutation, is CCM disease 
focal in nature?  To answer these questions, many in the field have proposed that CCM disease is 
caused by a 2-hit mechanism, much like cancer.  In this model, an individual who has a germline 
mutation in, for example, CCM1, will develop a CCM lesion if she acquires a somatic mutation 
in the other CCM1 allele in a brain endothelial cell.  As evidence for this model, sequencing of 
surgically resected CCM lesions from patients heterozygous for any of the three CCM-causing 
genes reveals biallelic mutations in that gene.  Although biallelic mutations could not be detected 17 
 
in every lesion, perhaps for technical reasons, the existence of biallelic mutations in even some 
lesions argues strongly for a two-hit model (Akers et al., 2009; Gault et al., 2009; Gault et al., 
2005).  In a variation of the classical two-hit model, it has also been proposed that the second hit 
could be environmental rather than genetic; for example, a vessel sensitized by one loss-of-
function allele of a CCM gene could become leaky in response to repeated assault by cytokines 
(Whitehead et al., 2009). 
  Mouse models have provided some support for the two-hit model of CCM disease.  
Ccm1
+/- and Ccm2
+/- mice do not develop CCMs.  However, this does not discount the two-hit 
model because the mice may simply not be long-lived enough to acquire the second mutation.  
(In humans, CCMs may take decades to develop.)  To accelerate the rate of mutation, one 
disease model uses mice heterozygous for Ccm1 and homozygous mutant for the mismatch 
repair component MutS homolog 2 (Msh2).  Interesting, approximately half of the Ccm1
+/-;Msh2
-
/- mice developed lesions in the central nervous system with histological similarity to human 
CCM lesions.  For technical reasons, these lesions could not be sequenced to confirm a second 
mutation; however, Ccm1 protein is absent in a mosaic fashion, consistent with the conclusion 
that a somatic mutation inactivates the second allele of Ccm1.  Mysteriously, in the same study, 
it was found that Ccm2
+/-;Msh2
-/- mice do not develop CCMs (McDonald et al., 2011).  
Regardless, administration of the ROCK inhibitor Fasudil decreases the CCM lesion burden in 
Ccm1
+/-;Msh2
-/- mice, demonstrating that the lesions that develop in this model fit with the data 
gathered from other studies of Ccm1 and Ccm2 heterozygotes and endothelial cell culture 
experiments.  Excitingly, this study suggests that RhoA pathway inhibitors may be useful in 
treating human CCM patients (McDonald et al., 2012). 
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The function of Ccm3 is mysterious 
 
Unlike other signaling pathways that have been studied extensively, the Heg-CCM 
pathway was discovered only recently and as a result remains mysterious in many ways.  
Questions abound as to the structure and function of this pathway.  One particularly challenging 
problem in the field is the role of CCM3.  There is evidence to suggest that CCM3 functions in 
the same pathway as CCM1 and CCM2.  First, mutations in CCM3 cause CCMs in humans 
(Bergametti et al., 2005).  Second, in overexpression studies, CCM2 binds CCM3 (Hilder et al., 
2007; Li et al., 2010; Voss et al., 2007; Zheng et al., 2010).  Third, knockdown of CCM3 in 
endothelial cell culture has been reported to cause an increase in RHOA activation (Borikova et 
al., 2010; Zheng et al., 2010).  Fourth, inactivation of the two zebrafish CCM3 paralogs, ccm3a 
and ccm3b, has been reported by two groups to confer a dilated heart phenotype (Voss et al., 
2009; Zheng et al., 2010).   
Recent studies, however, suggest that the relationship between CCM3 and CCM1/2 is 
more complicated.  In one report, Ccm2 and Ccm3 were each knocked out of the adult mouse 
endothelium, and both knockouts exhibited similar CCM pathology.  However, the same report 
found that the embryonic phenotypes caused by endothelial-specific deletion of Ccm2 or Ccm3 
are quite distinct.  These researchers also found that RhoA activation in endothelial cell culture is 
not increased by Ccm3 knockdown, leading them to conclude that loss of Ccm2 and Ccm3 cause 
CCM disease by different mechanisms (Chan et al., 2011).  In the same vein, a recent study by a 
different group reexamined the embryonic heart phenotype conferred by knockdown of ccm3a/b 
in zebrafish.  They found that, contrary to previous reports, ccm3a/b morphants have pericardial 
edema but no enlargement of the heart chambers, unlike san and vtn mutants, which have 19 
 
enormous hearts (Yoruk et al., 2012).  These findings are consistent with observations previously 
made in our laboratory (personal communication, JDM).  Moreover, ccm3a/b morphants exhibit 
an extreme dilation of cranial vessels, while san and vtn mutants do not, suggesting that ccm3a/b 
functions in a different pathway from ccm1 and ccm2 in zebrafish brain vasculature as well as in 
the heart (Yoruk et al., 2012).  Clearly defining the function of Ccm3 in development and disease 
will be an interesting and important challenge for the community of CCM researchers in the 
coming years. 
 
Zebrafish as a model to validate novel Heg-CCM pathway genes 
 
Since loss of components of the Heg-CCM pathway causes CCM disease in humans and 
embryonic heart defects in zebrafish, we have considered the strengths and weaknesses of the 
embryonic heart as a model for understanding CCM disease.  The main disadvantage of the 
zebrafish heart model as a means of understanding human disease is that a key aspect of cell 
biology is different in the two systems: san and vtn mutants have normal numbers of endothelial 
cells in the heart (Mably et al., 2006), while human CCMs exhibit endothelial hyperproliferation.  
An illustration of this disadvantage is provided by a study finding that CCM1-depleted HUVECs 
xenografted into mice develop CCM-like pathology, and that administration of the multiple 
kinase inhibitor Sorafenib could suppress the overproliferation of these cells (Wustehube et al., 
2010).  The zebrafish heart would not be a useful system for testing this sort of therapeutic.  
However, other aspects of cell biology are conserved between san and vtn hearts and human 
CCMs, such as the reduction in endothelial cell junctions (Kleaveland et al., 2009; Wong et al., 
2000).  The similarities and differences between the Heg-CCM mutant zebrafish hearts and 20 
 
human CCMs are summarized in Table 1.2.  Given the commonalities between the systems, we 
believe the mutant zebrafish heart has promise as a CCM model. 
 
Table 1.2.  A comparison of the genetics and phenotypes of the dilated zebrafish heart and 
human CCMs. 
 
  Zebrafish dilated 
heart  Human CCM 
Genes 
heg, ccm1, ccm2, 
ccm3a/b(?)  CCM1, CCM2, CCM3 
Inheritance  Recessive  Dominant 
Tissue affected  Heart endothelium 
(endocardium) 
Predominantly brain 
endothelium 
Histological 
phenotype 
Severe dilation  Severe dilation 
Cell biological 
phenotypes 
Reduced tight 
junctions 
Reduced tight junctions, 
over proliferation 
 
 
Why do san and vtn mutant embryos develop fatal heart defects, while patients with 
mutations in CCM1 and CCM2 develop lesions in their brain vasculature but maintain healthy 
hearts?  This is almost certainly due not to differences between species, but to the disparate 
effects of homozygous and heterozygous genotypes.  The san and vtn zebrafish mutants with 
massively dilated hearts are homozygous mutant, whereas human CCM patients are 
heterozygotes.  Since complete loss of Ccm1 or Ccm2 causes embryonic lethality in mouse due 
to defective cardiovascular development (Boulday et al., 2009; Whitehead et al., 2009; 
Whitehead et al., 2004), it stands to reason that any humans homozygous for mutations in either 21 
 
gene would probably die in utero from cardiovascular defects as well.  No CCM-like lesions 
have been detected in the brains of heterozygous zebrafish adults (personal communication, 
JDM); however, since it takes most humans decades to develop CCM disease, it might be that 
the zebrafish is simply not long-lived enough to acquire the disease, even though the Heg-CCM 
pathway functions similarly in the two species. 
Our comprehension of the Heg-CCM pathway in development and disease is limited not 
only by our lack of understanding about the interactions among the Heg-CCM genes, but also by 
the small number of genes known to participate in the pathway.  The latter point is highlighted 
by a human genetics study in which DNA sequencing was performed on patients with either 
familial or sporadic CCM disease.  The researchers found that 94% of familial cases and 57% of 
sporadic cases of CCMs could be explained by mutations in CCM1-3 (Denier et al., 2006).  
Thus, while most familial CCM cases are attributable to mutations in known CCM-causing 
genes, nearly half of all sporadic CCM cases are of unknown etiology.  It is very likely that the 
disease in these patients also has a genetic basis, and it is of great interest to identify candidate 
genes whose mutation could cause CCMs or enhance the pathology of CCMs caused by other 
factors. 
The zebrafish embryo is ideal for testing candidate CCM genes.  Any candidate genes 
can be rapidly knocked down by morpholino microinjection in large numbers of embryos, and 
the other embryological and genetic tools available in zebrafish can be used to analyze the 
relationship between the candidate gene and the known genes in the pathway.  The typical Heg-
CCM mutant phenotype—enlarged heart chambers, enlarged inflow tract, and lack of blood 
circulation—can be easily detected by low power light microscopy just two days after 22 
 
fertilization.  Any genes shown to interact with the Heg-CCM pathway in the zebrafish heart 
model would be intriguing candidates to investigate for roles in human CCM disease. 
 
ccm2-like 
 
  One method we used to identify genes with potential roles in the Heg-CCM pathway was 
to query the Ensembl database using BLASTp and BLASTx algorithms for proteins bearing 
identity to the known Heg-CCM components.  Our reasoning was that Ccm1, Ccm2, and Heg 
paralogs encoded by the zebrafish genome might also participate in the Heg-CCM pathway 
owing to their structural similarity to known Heg-CCM proteins.  We identified a novel protein, 
which we named Ccm2-like (Ccm2l), that has high identity to Ccm2.  In Chapter 2 of this 
dissertation, we present data that argue for a function for Ccm2l in the Heg-CCM pathway.  
While the relevant experiments were being performed, the function of ccm2l had not been 
analyzed in any species.  While this dissertation was in preparation, however, a study of the 
function of Ccm2l in mouse was published (Zheng et al., 2012).  Here I provide a summary of 
their findings without reference to our work.  In the Discussion section of Chapter 2, I analyze 
the similarities and differences between the findings of Zheng et al. in mouse and ours in 
zebrafish. 
  Mouse Ccm2-like (Ccm2l) was identified by querying the EST and Ensemble databases 
with the Ccm2 sequence.  Although Ccm2l is expressed in a subset of endothelial cells, including 
those in the heart, Ccm2l knockout mice lack overt cardiovascular defects; they survive to 
adulthood and are apparently normal.  Interestingly, Ccm2l
-/-;Heg1
-/- mice suffer embryonic 
lethality due to severe heart defects; these double mutants exhibit an unusually thin myocardium, 23 
 
reduced ventricular trabeculation, and dilated atria.  Heg1
-/- null embryos often survive through 
embryonic development but die postnatally from similar cardiac defects.  Thus, complete loss of 
Ccm2l produces no phenotype by itself, but can enhance the heart defects in Heg1
-/- mice.  The 
authors conclude that Heg1 and Ccm2l function together in a pathway (Zheng et al., 2012). 
Interestingly, Ccm2l
-/-;Heg1
-/- heart defects can be rescued by loss of one Ccm2 allele; 
50% of Ccm2l
-/-;Heg1
-/-;Ccm2
+/- mice survive through embryonic development, whereas Ccm2l
-/-
;Heg1
-/-;Ccm2
+/+ mice never do.  Moreover, branchial arch defects in Ccm2
+/-; Heg1
-/- can be 
suppressed by loss of both alleles of Ccm2l.  The authors propose that Ccm2 and Ccm2l oppose 
each other in cardiovascular development (Zheng et al., 2012). 
  The notion of competition between Ccm2 and Ccm2l is also supported by cell culture 
data.  Like Ccm2, Ccm2l has a PTB domain through which it binds Ccm1.  In overexpression 
assays, Ccm2 and Ccm2l compete for binding to Ccm1.  Forced expression of Ccm2l in 
endothelial cells causes an increase in activated RhoA and a decrease in monolayer permeability, 
consistent with disruption of Ccm1-Ccm2 binding.  Unlike Ccm2, Ccm2l cannot bind Ccm3, and 
the authors believe this difference explains the disparate effects of Ccm2 and Ccm2l on RhoA 
activation and the concomitant mouse endothelial phenotypes (Zheng et al., 2012). 
    In the model proposed by Zheng et al., competition in the endothelium between Ccm2 
and Ccm2l for binding to the Heg-Ccm1 complex regulates cardiovascular development.  When 
Ccm2 binds the Heg-Ccm1 complex, RhoA signaling is suppressed and vascular stability is 
achieved through the maintenance of cell junctions.  However, when Ccm2l binds the Heg-Ccm1 
complex, a program for vascular growth is induced, and in the endocardium, growth factors that 
promote myocardial proliferation are released.  Their model explains why loss of Heg1 enhances 
both the branchial arch defects in Ccm2
+/- embryos (failure to lumenize due to defective cell 24 
 
junctions) and the heart defects in Ccm2l
-/- embryos (insufficient myocardial growth), and why 
both of those phenotypes can be partially rescued by a reduction in gene dosage of the other 
paralog (Zheng et al., 2012). 
 
This work 
 
  The experiments presented herein are a study of the structure and function of the Heg-
CCM pathway.  First, we study the Heg protein, and investigate its post-translational processing 
in cell culture and perform a yeast 2-hybrid screen to identify proteins that interact with its 
intracellular domain.  We find that zebrafish Heg and Ccm1 proteins interact.  Second, we use 
the zebrafish model to analyze the function of ccm2l.  We conclude that ccm2l is required for 
normal heart development to occur and that ccm2l and ccm2 have partially overlapping 
functions.  Finally, we investigate the relationship between the Heg-CCM pathway and the ERK 
signaling system in cell culture and the zebrafish heart.  We present evidence that the Erk 
pathway functions downstream of or parallel to the Heg-CCM pathway in regulating the size of 
the heart.  These studies elucidate the function of the Heg-CCM pathway in regulating heart 
development, and it is our hope that they may provide insights into human CCM disease. 
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Attributions 
 
  The overall experimental design for the project described in this chapter was a 
collaboration between Jonathan Rosen and John Mably, and all experiments were performed by 
Jonathan Rosen, with the exception of the bioinformatics related to the yeast 2-hybrid screen, 
which were performed by John Mably.  Grigory Krapavinsky contributed the idea of validating 
yeast 2-hybrid hits by performing co-immunoprecipitations with in vitro translated proteins, and 
he also shared the relevant protocol.  Various reagents were kind gifts from colleagues, as noted 
in Materials and Methods.  Some of the text in Materials and Methods is modified from our 
submitted (with revisions) manuscript “ccm2-like is required for cardiovascular development as a 
novel component of the Heg-CCM pathway,” in review at the time of the writing of this 
dissertation. 
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Introduction 
 
  In zebrafish, the heart of glass (heg), santa (san), and valentine (vtn) mutants—which 
have mutations in the genes heg, cerebral cavernous malformation 1 (ccm1), and cerebral 
cavernous malformation 2 (ccm2), respectively— exhibit a dramatic dilation of the embryonic 
heart chambers and a loss of blood circulation.  The near-identical nature of the heart phenotype 
in the three mutants immediately suggests the possibility that the three genes operate in a 
common pathway.  This conjecture was confirmed by morpholino coinjection experiments 
showing that each gene genetically interacts with the other two (Mably et al., 2006; Mably et al., 
2003).  heg, ccm1, and ccm2 function as core components of the Heg-CCM pathway. 
  The Heg-CCM pathway is also required for cardiovascular development in mouse 
(Boulday et al., 2009; Kleaveland et al., 2009; Whitehead et al., 2009; Whitehead et al., 2004).  
Selective deletion of Ccm2 from the developing endothelium recapitulates the whole-organism 
knockout phenotype, implying that the Heg-CCM pathway regulates cardiovascular development 
through its activity in that tissue (Boulday et al., 2009; Whitehead et al., 2009).  This is likely 
also true in zebrafish, as heg is detectable in the heart’s endocardium (Mably et al., 2003) and 
ccm1 has been shown to have cell-autonomous functions in the posterior cardinal vein (PCV), an 
extra-cardiac endothelial vessel (Hogan et al., 2008). 
  The cellular functions of ccm1 and ccm2 have been investigated in considerable depth.  
Both genes encode cytoplasmic proteins.  Ccm1 contains ankyrin repeats, a 
4.1/ezrin/radixin/moesin (FERM) domain and three NPXY/F motifs.  Ccm2 contains a PTB 
domain.  Ccm1 and Ccm2 bind in an interaction that requires the NPXY/F motifs of Ccm1 and 
the PTB domain of Ccm2 (Zawistowski et al., 2005; Zhang et al., 2007).  In endothelial cell 32 
 
culture, CCM1 and CCM2 localize to endothelial cell junctions (Glading et al., 2007; Stockton et 
al., 2010), a finding that correlates with the defects in junctional integrity observed in both cell 
culture systems and mice when these proteins are depleted (Glading et al., 2007; Stockton et al., 
2010; Whitehead et al., 2009).   
  In contrast to Ccm1 and Ccm2, little is known about Heg protein.  Heg is a single-pass 
transmembrane protein with a highly conserved intracellular domain and a large extracellular 
region containing epidermal growth factor (EGF)-like repeats; the extracellular region is 
predicted to be heavily glycosylated (Mably et al., 2003).  Based on what little is known about 
Heg, it is easy to imagine numerous mutually non-exclusive ways it could function in the cell.  
Since Ccm1 and Ccm2 localize to the membrane, it could serve to recruit or anchor them there.  
One can also imagine it serving as a signaling receptor, transducing signals into the cell upon 
binding to an unidentified extracellular ligand.  The reverse is equally plausible, as Heg could act 
as a ligand by binding signaling receptors on adjacent cells.  (In zebrafish heg mutants, the 
myocardium remains a single-cell layer instead of thickening as in wildtype embryos, and it is 
interesting to speculate that Heg might directly signal to the myocardium to regulate myocardial 
growth.)  Alternatively, Heg could function as a junctional protein whose extracellular domain 
binds the extracellular domains of other transmembrane proteins on nearby cells to promote 
proper tissue architecture. 
To begin to distinguish among these possibilities, we performed a yeast 2-hybrid screen, 
the analysis of which comprises the majority of this chapter.  We reasoned that the identification 
of proteins that bind the intracellular domain of Heg would provide vital clues to its function.  
While this experiment was in progress, two important reports came out pertaining to the function 
of Heg.  First, it was shown that Heg expression in the endothelium of the embryonic zebrafish 33 
 
liver regulates the polarity of adjacent hepatocytes, raising the possibility that Heg functions as 
an endothelial-derived ligand in some contexts (Sakaguchi et al., 2008).  Second, it was reported 
that the mammalian homologs of Heg and Ccm1 interact, and that Heg has a role in regulating 
endothelial cell junctions in mouse (Kleaveland et al., 2009).  Our yeast 2-hybrid screen using 
zebrafish genes detects an interaction between Heg and Ccm1, demonstrating that this physical 
interaction is conserved across species and suggesting that other mechanistic aspects of Heg-
CCM signaling may be conserved as well. 
 
Materials and methods  
 
Cell culture, immunoprecipitation and western blotting 
  Human umbilical vein endothelial cells (HUVECs) were maintained in EGM-2 media as 
per the manufacturer’s instructions (Lonza).  HUVECs at 60% confluence were transfected with 
siRNAs at concentrations of 10 nM or 30 nM using Silentfect reagent (Bio-rad) and Opti-mem 
(Life Sciences). The day after transfection, media was refreshed, and three days after transfection 
cells were washed in phosphate buffered saline (PBS) and lysed in radioimmunoprecipitation 
assay (RIPA) buffer with Complete protease inhibitor (Roche) or Trizol (Life Sciences) for 
generation of protein lysates or isolation of total RNA, respectively.  The following silencer 
select siRNAs (Life Sciences) targeting HEG1 were used: s33148, s33149, and s33150.  Silencer 
Negative Control siRNA #1 and GAPDH siRNA (Life Sciences) were also used. 
293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 
10% fetal bovine serum.  Cells at 80%-100% confluence were transfected using Lipofectamine-
2000 reagent essentially as per the manufacturer’s instructions (Life Sciences).  Two days after 34 
 
transfection, cells were washed in PBS and lysed in immunoprecipitation buffer (30 mM Tris, 
150 mM NaCl, 1% Triton X100, and Complete protease inhibitor (Roche)).   Cleared lysates to 
be used for immunoprecipitation experiments were incubated with antibody-conjugated agarose 
beads for two hours to overnight; beads were then washed several times in cold 
immunoprecipitation buffer.  Agarose beads pre-conjugated to the following antibodies were 
used: anti-FLAG (Sigma), anti-Myc (Clontech), anti-HA (Roche). 
HUVEC and 293T cell protein samples were diluted in NuPAGE LDS sample buffer 
(Life Technologies) containing DTT (final concentration 50 µM), incubated at 80°C for ten 
minutes, and electrophoresed on a precast acrylamide gel (Life Technologies) at 200 V. Proteins 
were immobilized on PVDF paper by wet transfer at 33V for 1 to 1.5 hours. PVDF papers were 
blocked in PBS with 0.1% tween-20 (PBT) containing 5% milk and blotted with the following 
antibodies in blocking solution for 1 hour at room temperature or overnight at 4 °C: FLAG M2-
peroxidase 1:1000 (Sigma), HA-peroxidase 1:1000 (Roche), V5-HRP 1:2500 (Life Sciences), 
myc-HRP 1:1500 (Roche), Heg antibody HM2148 1:500 (see next paragraph), GAPDH 1:25000 
(Millipore). Blots probed with anti-Heg antibody or anti-GAPDH antibody were washed three 
times and then incubated for one hour with peroxidase-conjugated anti-rabbit or anti-mouse 
antibodies (GE Healthcare), respectively, in blocking solution at 1:2500. After antibody 
incubation, blots were washed three times in PBT before developing with SuperSignal West Pico 
Substrate or SuperSignal West Dura Chemiluminescent Substrates (Thermo Scientific) as per the 
manufacturer’s instructions. 
  A polyclonal antibody to the C-terminal region of Heg was generated by immunizing 
rabbits with a synthetic peptide designed from conceptual translation of the open reading frame. 
For the Heg C-terminal epitope antibody HM2148, the peptide PSFLSDDSRRRDYF was 35 
 
synthesized, then conjugated at the N-terminus to KLH (Keyhole Limpet Hemocyanin) through a 
Cys-6-carbon spacer (Princeton Biomolecules). Rabbits were injected with the peptide 
immunogen using a typical schedule (initial sub-cutaneous injection of 500 µg followed by 5 
additional boosts with 250 µg at 21 day intervals; Covance Research). The terminal 
exsanguination was completed at 118 days after initiation of the protocol and this serum was 
then affinity purified. 
For experiments with lactacystin, chemical was added at a concentration of 10 µM 24 
hours after transfection, and lysates were made 12 hours later.  For the peptide competition 
assay, anti-Heg antibody was incubated in PBS with 100 molar excess of either N-terminal Heg 
peptide or C-terminal peptide prior to western blotting. 
 
  Plasmids 
  The pGBKT7-HegICD yeast 2-hybrid bait vector was generated by performing PCR on a 
Heg clone template with primers designed to amplify the sequence corresponding to Heg’s 
intracellular domain.  The primers contained EcoRI and BamHI restriction sites, and following 
PCR, the product was digested and ligated into pGBKT7, which had been digested with the same 
enzymes.  The following primers were used: 5’-TTTGAATTCAAAAAAGACAAAAACGAC-
3’, 5’-TTTGGATCCTCAAAAGTAGTCTCTTCG-3’.  pCMV-HA-HegICD was generated by 
shuttling the insert from pGBKT7 into pCMV-HA using EcoRI and SalI.  FLAG-tagged preys to 
be expressed in 293T cells were excised from the pGADT7 yeast 2-hybrid screening vector with 
EcoRI and XhoI and ligated into pCMVtag2b.  Ccdc80a-FLAG was generated by performing 
PCR on a ccdc80a clone with primers containing HindIII and EcoRI sites and ligating the 
products into pRK7 modified to contain a C-terminal FLAG tag (donated by Jamie Dempsey and 36 
 
John Blenis).  The following primers were used: 5’-
CCCCAAGCTTGCCACCATGAGGGCACGGTATATGCTTGGTTTC-3’, 5’-
CCCCGAATTCATATCCATAACCCTGATGATA-3’.  Full-length zebrafish heg was cloned 
into pCMV-Myc (Clontech) following PCR on a heg template (Open Biosystems clone 903796) 
using forward and reverse primers containing EcoRI and XhoI cut sites, respectively.  The 
following primers were used:  
5’-GATCGAATTCAAATGATGGAAACGTGCGCTCG-3’,  
5’-GATCCTCGAGTCAAAAGTAGTCTCTTCGGCGTG-3’.  
FLAG-mheg-V5 was a gift from Mark Kahn.  TrpM7 plasmids were a gift from Grigory 
Krapavinsky 
 
Yeast 2-hybrid Screen 
  The yeast 2-hybrid screen was performed using the Matchmaker 2-hybrid system, as per 
the manufacturer’s instructions (Clontech).  For bait, we subcloned DNA corresponding to the 
intracellular domain of Heg into pGBKT7 as described above.  For preys, we used a library 
containing inserts isolated from 3 day-old zebrafish hearts cloned into a modified pGADT7-
RecAB vector.  The library was a generous gift from Geoff Burns.  Plasmids were recovered 
from positive colonies using the Easy Yeast Plasmid Isolation Kit (Clontech). 
 
in vitro transcription/translation 
  in vitro transcription/translation was accomplished using the TNT Quick Coupled 
Transcription/Translation System (Promega) without radioactivity.  Prey plasmids from the 
screen could be used without further subcloning.  Each reaction contained 200 ng of plasmid in a 37 
 
final volume of 10 µl.  Following translation 5 µl of each prey was incubated with 5 µl of Myc-
Heg-ICD for 30 minutes, at which point 290 µl immunoprecipitation buffer was added along 
with myc antibody-conjugated beads.  Pulldowns and western blots were performed as described 
above. 
 
RT-PCR 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was done with 
the QuantiFast SYBR Green RT-PCR Kit (Qiagen) as per the manufacturer’s instructions on 
RNA samples extracted with Trizol (Life Sciences).  The following primers were used.  GAPDH: 
5’-ATTCCATGGCACCGTCAAGG -3’, 5’-GAGGGATCTCGCTCCTGGAA -3’, HEG1:  5’- 
ACCACTCCTGCCGAGCATGT-3’, 5’-GCGGCTGCGATCACCACAGT-3’. 
 
Zebrafish experiments 
  Freshly fertilized zebrafish embryos were injected with morpholino as previously 
described (Rosen et al., 2009).  The following morpholinos (Gene Tools) were used. 
ccdc80a e3i3: 5’- GTTTTATTGCTAGTGTTACCTTCGC-3’, 
ccdc80a: e5i5 5’-GTGAACCATCTCTTACCCAGGTTGC-3’, 
Standard control morpholino: 5’-CCTCTTACCTCAGTTACAATTTATA-3'. 
In experiments to characterize the ccdc80a knockdown phenotype, we injected 0.5 pMol 
ccdc80a e3i3 or ccdc80a e5i5 morpholino. For enhancer experiments, pairwise combinations of 
morpholino were injected as single solutions.  Each 1 nL injection volume contained 0.01 pMol 
ccm1 MO + 0.2 pMol ccdc80a e3i3 MO, 0.01 pMol ccm1 MO +  0.2 pMol standard control MO, 38 
 
or 0.01 pMol standard control MO + 0.2 pMol ccdc80a e3i3 MO.  Solutions were blinded to the  
experimenter prior to injection and revealed after embryos were assayed at 2 dpf. 
 
Microscopy 
  Live zebrafish embryos were mounted in 4% methyl cellulose on a microscope 
slide without a coverslip.  Images were taken with a Nikon Eclipse 90i microscope equipped 
with a CoolSNAP HQ2 camera (Photometrics) using NIS-Elements software.  Images were then 
processed in Adobe Photoshop. 
 
Results 
 
The C-terminal end of Heg is cleaved 
  Endothelial cell culture has been invaluable in dissecting the cellular functions of ccm1 
and ccm2 in studies such as Glading et al., 2007 and Whitehead et al., 2009.  For cell culture 
experiments studying heg, we used primary Human Umbilical Vein Endothelial Cells 
(HUVECs).  First, we determined by RT-PCR that the human homolog of zebrafish heg, HEG1, 
is expressed in HUVECs (Figure 2.1A).  Next, we tested three siRNAs against HEG1 in 
HUVECs and found by quantitative RT-PCR that all three could efficiently knock down HEG1 
transcript (Figure 2.1B). 
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Figure 2.1.  Validation of tools for studying Heg in cell culture.  (A) RT-PCR detects HEG1 
transcripts in HUVECs as well as 293T cells.  Ubiquitously expressed GAPDH is a positive 
control for RNA isolation and RT-PCR methodology, and water is a negative control showing 
that signal is not the result of contamination.  (B) si33148, si33149, and si33150 all efficiently 
knock down HEG1 in HUVECs at both 10 nM and 30 nM.  Bars represent the ratio of  HEG1 
transcript in experimental (or untransfected) samples to HEG1 transcript in a sample transfected 
with negative control siRNA, all normalized to GAPDH expression levels.  Error bars represent 
the standard error from three technical replicates of the same biological sample.  (C) Anti-Heg 
and anti-HA antibodies detect overexpressed HA-HegICD protein in 293T cell lysates.  In each 
blot, the first lane is protein immunoprecipitated with HA antibody-conjugated beads following 
overexpression of HA-HegICD and a FLAG-tagged Ccm1 fragment.  The second lane is the 
input from the same sample.  (D) Anti-Heg antibody detects endogenous HEG1 in HUVEC 
lysates.  Two strong bands (arrows) and a faint band (arrowhead) show Heg protein specifically 
in samples that were untransfected or transfected with scrambled siRNA or siRNA against 
GAPDH.  These bands are absent or drastically reduced in samples transfected with anti-Heg 
siRNAs 33148, 33149, and 33150, at either 10 nM or 30 nM.  There are also several nonspecific 
bands detected by the antibody. 
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We then validated a polyclonal antibody, HM2148, generated against a peptide 
corresponding to the C-terminal (intracellular) region of Heg.  First, we confirmed that the anti-
Heg antibody could detect a tagged protein corresponding to the intracellular domain of Heg 
(HA-HegICD) upon overexpression in 293T cells.  This interaction could be competed away by 
addition of C-terminal Heg peptide but not N-terminal Heg peptide (Figure 2.1C).  Next, we 
tested the ability of the anti-Heg antibody to detect endogenous Heg in HUVECs.  We found that 
it detected multiple protein species in lysates made from HUVECs that were untransfected, 
transfected with a negative control siRNA, or transfected with siRNA against GAPDH.  These 
bands were absent or drastically reduced in lysates made from HUVECs that had been 
transfected with any of three different anti-Heg siRNAs (Figure 2.1D).  The largest Heg-specific 
band runs at a molecular weight greater than 195 kDa.  This is larger than 107 kDa, the expected 
size of full-length Heg, which suggests that Heg is subject to post-translational modifications.  
Indeed, based on its amino acid sequence, Heg is predicted to be heavily glycosylated. 
Surprisingly, we found that in addition to the large bands presumably corresponding to 
full-length Heg protein, we were able to faintly detect a specific band between 15 and 20 kDa 
(barely visible in Figure 2.1D, arrowhead).  Two explanations for the presence of this small band 
are that it represents a cleavage product derived from the mature protein or an isoform translated 
from an alternatively spliced transcript.  To distinguish between these possibilities, we 
overexpressed a doubly tagged mouse Heg construct, FLAG-mHeg-V5, in 293T cells.  Since this 
construct contains only exonic DNA and hence cannot be spliced, we reasoned that the presence 
of the small band (detected by anti-V5 antibody) in this lysate would strongly suggest that the 
small protein species is the result of a cleavage event.  We observed the small molecular weight 
band when blotting with an antibody against the C-terminal V5 tag, but not with an antibody 41 
 
against the N-terminal FLAG tag (Figure 2.2A).  To compare the sizes of the endogenous small 
Heg product and the overexpressed small Heg product, we ran HUVEC and transfected 293T 
cell lysates on the same acrylamide gel and observed that the products are nearly the same size 
(Figure 2.2B).  Taken altogether, we conclude that the C-terminal end of Heg is cleaved in 
endogenous protein in HUVECs and in overexpressed protein in 293T cells.  The functional 
significance of this cleavage event remains mysterious and should be an interesting subject of 
inquiry in future research. 
 
 
Figure 2.2.  The C-terminal end of Heg is cleaved.  (A) The C-terminal end of Heg is cleaved 
when FLAG-mHeg-V5 is overexpressed in 293T cells.  Blotting with antibody against FLAG, 
the N-terminal epitope tag, generates a large band.  Blotting with antibody against V5, the C-
terminal epitope tag, produces a smear likely corresponding to differentially glycosylated species 
of full-length Heg, and a much smaller band slightly larger than 15 kDa. (B) The small Heg band 
present in HUVEC lysates (faintly visible in figure 1D) runs at approximately the same size as 
the small Heg band in FLAG-mHeg-V5 overexpressing 293T cells.  To allow for an accurate 
comparison of sizes, these samples were all run on the same acrylamide gel.  FLAG-TrpM7 frag 
(fragment) is an irrelevant protein included to show that the V5 signal for FLAG-mHeg-V5 is 
specific.  The anti-Heg antibody also detects a smaller nonspecific band. 42 
 
 
 
Yeast 2-hybird screen identifies an interaction between Heg and Ccm1 
  To explore the cellular function of Heg protein, we performed a yeast 2-hybrid screen to 
identify proteins that interact with Heg.  As bait, we used a protein in which the binding domain 
of GAL4 is fused to HegICD.  HegICD was used rather than full-length Heg because the yeast 2-
hybrid assay requires translocation of proteins to the yeast nucleus, a process that would likely be 
impeded by the transmembrane domain of full-length Heg.  Moreover, HegICD is the most 
highly conserved part of the protein, suggesting that it may be a particularly important domain 
within Heg.  The prey in the yeast 2-hybrid screen were gene fragments isolated from 3 day-old 
embryonic zebrafish hearts, fused to the activating domain of GAL4.  In response to an 
interaction between bait and prey, HIS and lacZ are transcribed (Figure 2.3A).  The former 
allows for selective growth on yeast media lacking histidine, and the latter is used in a follow-up 
assay in which yeast colonies expressing the lacZ reporter turn blue after treatment with 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal). 
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Figure 2.3.  Overview of yeast 2-hybrid screen.  (A) Schematic showing yeast 2-hybrid screen.  
When prey proteins bind HegICD, GAL4-AD and GAL4-BD are brought into contact and 
transcribe the HIS and LacZ reporter genes.  As a result, only clones expressing preys that 
interact with HegICD grow on selective media lacking histidine.  (B) As a secondary assay for 
reporter gene activity, clones were grown on filter paper, permeabilized by liquid nitrogen, and 
subjected to X-gal staining.  Formation of a blue product indicates lacZ expression.  The 
horizontal arrow indicates a rare negative result in this assay.  (C) A table of the most highly 
represented genes among the recovered yeast 2-hybrid clones. 
 
We screened approximately 740,000 clones and selected 289 colonies that grew on 
selective media for further analysis. In the first step to validate these clones, they were restreaked 
on the same selective media and subjected to X-gal staining.  281 of the 289 colonies both 
regrew and tested positive in the X-gal assay (Figure 2.3B). We attempted to amplify the insert 
in all 281 colonies by PCR.  We sent 254 amplified inserts for sequencing; the remainder either 
showed no PCR product or multiple PCR products. The insert sequences were arranged into 
contigs and queried against a reference RNA database using the TBLASTX algorithm to 44 
 
determine what genes they represented.  A complete list of the preliminary yeast 2-hybrid hits is 
in this dissertation’s appendix. 
 We ranked the yeast 2-hybrid genes by how highly represented they were among the 
clones recovered from the screen (for top hits, see Figure 2.3C).  We followed up several top hits 
by testing whether they co-immunoprecipitate with HA-HegICD in the 293T cell overexpression 
system (Figure 2.4A).  Our top hit, titin A (ttna), was excluded from this analysis because of its 
well understood function in the heart myocardium; collagen 1a (col1a) was excluded because it 
was previously found by a colleague in a different yeast 2-hybrid screen to activate reporter gene 
expression in the absence of bait protein (personal communication, Geoff Burns).  We found that 
only #256 immunoprecipitated with HegICD.  #256 represents a fragment of ccm1, a known 
genetic interactor of heg (Mably et al., 2006).  These results demonstrate that the proteins 
encoded by these two zebrafish genes can physically interact, and while our research was in 
progress, this was demonstrated by others for the mammalian orthologs (Kleaveland et al., 
2009). 45 
 
 
Figure 2.4.  Biochemical validation of yeast 2-hybrid hits.  (A) Several top yeast 2-hybrid hits, 
tagged with the FLAG epitope, were cotransfected into 293T cells with HA-HegICD.  Only 
FLAG-256, corresponding to ccm1, was co-immunoprecipitated with HA-HegICD  by anti-HA 
conjugated agarose beads.  A TrpM7 fragment was included as an irrelevant protein control.  (B) 
In the same assay, FLAG-217, corresponding to cstf1, does not bind HA-HegICD.  FLAG-256 is 
a positive control for HegICD interactions, and HA-TrpM7 and FLAG-TrpM7 are irrelevant 
protein controls for specificity.  (C) Thirty-four HA-tagged clones (“preys”) recovered from the 
yeast 2-hybrid screen were transcribed and translated in vitro and incubated with Myc-HegICD 
protein generated in the same fashion.  We then immunoprecipitated Myc-HegICD with anti-
myc antibody-conjugated beads and blotted pulldowns with anti-HA antibody to determine 
which preys interact with HegICD.  As a control, we simultaneously tested prey proteins (from 
the same in vitro translation reactions) for their ability to bind beads in the absence of Myc-  
HegICD.  Interactors in this assay are defined as proteins that are immunoprecipitated more 
efficiently in the presence of Myc-HegICD.  This assay argues for clones #256 (ccm1) and #217 
(cstf1) being interactors, as shown in red boxes.  The left-most column of experiments (myc 
input blot and pulldowns 40 through NO DNA) were performed on one date and the three 
rightmost columns (pulldowns 11 through 289) were performed on a later date.  Clones tested 
represent the following genes: 40: smarcb1a, 51: hmcn1, 132: flna, 176: integral membrane 
protein, 230: cilp, 231: rnf2, 256: ccm1, 259: cyclic nucleotide binding protein, 11: smox, 30: 
mapre1b, 38: cpt1a, 50: sart3, 59: aldob, 95: ptp4a3, 129: ccdc80, 134: col1a2, 150: aip, 152: 
fbln2, 154: pih1d1, 175: hbs1l, 178: ndufs2, 184: smad6, 189: cpt1a, 196: lox, 205: tbxa2r, 217: 
cstf1, 223: cdc20, 232: postn, 234: dhrs4, 241: il23r, 256: ccm1, 257: adam12, 261: htra2, 288: 
flnb, 289: nid2. 46 
 
   
We then decided to cast a wider net and screen a larger number of initial yeast 2-hybrid 
hits for physical interactions with HegICD.  We generated protein from Myc-HegICD and HA-
tagged prey clones by a coupled in vitro transcription/translation reaction and then incubated 
them together and tested which preys were co-immunoprecipitated with Myc-HegICD by anti-
myc antibody-conjugated agarose beads (Figure 2.4C).  As a negative control, we also tested 
whether prey proteins could bind directly to the beads in the absence of Myc-HegICD protein.  
We tested 34 preys in this fashion, including the five hits we had previously tested for 
interactions with HegICD in 293T cells.  We found that 29 preys expressed protein in this assay, 
and only two preys were more efficiently immunoprecipitated in the presence of Myc-HegICD 
than by beads alone.  These two hits were #256, the fragment of ccm1, and #217, a fragment of 
cleavage stimulation factor, 3' pre-RNA, subunit 1 (cstf1). 
While we had previously shown an interaction between clone #256 and HA-HegICD in 
293T cell culture (Figure 2.4A), we were unable to identify an interaction between #217 and 
HA-HegICD in that system (Figure 2.4B).  This analysis was complicated by an unusual feature 
of HA-HegICD protein: we found that following transfection, it is expressed at extremely low 
levels unless it is co-expressed with Ccm1 protein (Figure 2.5A).  Treatment of transfected cells 
with the proteosome inhibitor lactacystin dramatically increased the level of HegICD protein 
(Figure 2.5B).  These observations together suggest that HegICD is degraded by the proteosome 
and its interaction with Ccm1 can prevent this degradation.  We did not observe this 
phenomenon with the cleaved Heg product following transfection with full-length Heg (Figure 
2.5C), so we believe it is an artifact related to the HegICD construct rather than a biologically 
meaningful finding.  In the context of validating yeast 2-hybrid hits, the proteosomal degradation 47 
 
of HegICD makes it challenging to interpret immunoprecipitation data, as HegICD is often 
undetectable in inputs unless Ccm1 is present.  Because HegICD is present at such a low level in 
samples cotransfected with clone #217, we cannot state with confidence that the lack of HegICD 
immunoprecipitated by #217 means that the two proteins do not bind.  However, we think it is 
likely that if the two proteins did bind, the stability of HegICD would be enhanced, as with 
HegICD and Ccm1.  Regardless, in the absence of convincing data that HegICD binds #217, we 
chose to discontinue our studies of that clone. 
   48 
 
 
   
Figure 2.5.  Protein derived from a HegICD construct is labile and stabilized by Ccm1.  (A) 
Decreasing amounts of the Ccm1 construct FLAG-256 were transfected with constant amounts 
of HA-HegICD in 293T cells.  The amount of HA-HegICD protein present 24 hours after 
transfection correlates with the amount of FLAG-256 protein expression.  (B) Addition of the 
proteosome inhibitor lactacystin to cell media increases the level of HA-HegICD protein.  (C) 
Lactacystin treatment does not affect the level of the C-terminal Heg cleavage product following 
transfection with the full-length Heg construct FLAG-mHeg-V5. 
 
Zebrafish Ccm1, which is 741 amino acids long, contains a large C-terminal FERM 
domain comprising amino acids 414-638.  The smallest ccm1 clone recovered from the yeast 2-
hybrid screen codes for Ccm1 amino acids 416-741, suggesting that the FERM domain of Ccm1 49 
 
is sufficient to bind HegICD.  Based on our co-immunoprecipitation experiments in Chapter 3 of 
this dissertation, this is indeed the case. 
  We followed up one other hit from the yeast 2-hybrid screen in considerable detail even 
though it failed to interact with HegICD in the in vitro transcription/translation co-
immunoprecipitation experiment.  Clone #129 represents coiled-coil domain containing 80a 
(ccdc80a), one of three zebrafish ccdc80 paralogs.  Human CCDC80 has been shown to 
negatively regulate the Wnt/β-catenin signaling pathway in adiopose cell culture (Tremblay et 
al., 2009).  Similarly, ccm1 has been shown to suppress β-catenin signaling in endothelial cells 
(Glading and Ginsberg, 2010).  Due to this common function of CCDC80 and the Heg-CCM 
pathway member ccm1, we performed additional experiments to determine whether Ccdc80a and 
Heg interact genetically and physically. 
  We designed two non-overlapping morpholinos against exon-intron junctions in ccdc80a 
to determine the phenotype caused by loss of ccdc80a function.  Both morpholinos caused 
enlarged atria and inflow tracts in 48 hpf embryos (Figure 2.6A).  The morpholinos were 
validated by RT-PCR followed by sequencing; MO e3i3 causes a partial excision of exon 3 
leading to a frameshift event and an in-frame stop codon in exon 4, and MO e5i5 causes the 
inclusion of intron 5, which also has an in-frame stop codon (Figure 2.6B). 
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Figure 2.6.  ccdc80a is required for heart development but does not interact with the Heg-
CCM pathway.  (A) Two different morpholinos targeting exon-intron junction in ccdc80a 
confer a dilated atrium and inflow tract phenotype.  (B) RT-PCR showing activity of ccdc80a 
morpholinos.  Irrelevant lanes have been cropped from the lower image. (C) ccdc80a morpholino 
e3i3 is no more effective than control morpholino in enhancing the dilated heart phenotype in 
embryos sensitized by slight ccm1 knockdown.  (D) FLAG-tagged versions of TrpM7 (an 
irrelevant protein control), full-length Ccdc80a, and a yeast 2-hybrid fragment isolated from the 
yeast 2-hybrid screen all co-immunoprecipitate overexpressed Heg in 293T cells. a, atrium; i.t., 
inflow tract. 
 
  The phenotypes observed are consistent with a role for ccdc80a in the Heg-CCM 
pathway.  However, using a morpholino coinjection enhancer assay (see Materials and Methods), 
we found that ccdc80a knockdown does not enhance the dilated heart phenotype in embryos 
sensitized by a subphenotypic dose of morpholino against ccm1 (Figure 2.6C).  We also failed to 
detect a specific interaction between Heg and Ccdc80a proteins in the 293T cell overexpression 51 
 
system (Figure 2.6D).  Both full-length FLAG-Ccdc80a and the FLAG-tagged Ccdc80a 
fragment isolated from the yeast 2-hybrid screen co-immunoprecipitated Heg; however, a 
FLAG-tagged fragment of TrpM7, chosen as an irrelevant negative control protein, co-
immunoprecipitated Heg as well.  We conclude that overexpressed Heg protein in 293T cells 
binds too promiscuously for this assay to reliably identify specific interactions.  (This limitation 
does not apply to our analysis of Heg-Ccm1 interactions in Chapter 3.  In that set of experiments, 
the Ccm1 protein lacking a FERM domain does not bind Heg, providing an internal control for 
specificity.) 
 
Discussion 
 
Possible functions of the Heg cleavage event 
  The experiments in this chapter investigated Heg protein, a critical component of the 
Heg-CCM pathway.  We studied the processing of Heg protein by performing western blots for 
overexpressed Heg in 293T cells and endogenous Heg in HUVECs.  In both cases, we observed 
that antibodies against the C-terminal end of Heg detect multiple bands.  As expected, there are 
large molecular weight bands centered around 195 kDa that likely correspond to full-length Heg 
proteins bearing various degrees of glycosylation.  Surprisingly and interestingly, there is also a 
small molecular weight band that runs slightly above 15 kDa.  Because this band is detectable in 
lysates from 293T cells overexpressing Heg cDNA that lacks introns, it probably does not 
represent an isoform generated by alternative splicing.  We believe the most likely explanation 
for the existence of this small molecular weight product is that the C-terminal (intracellular) end 
of Heg is cleaved from the full-length protein. 52 
 
  We currently have no data speaking to the function of this cleavage event, but it is 
interesting to speculate that it is regulates the activity of the Heg-CCM pathway.  One can 
imagine several ways this could happen.  It is thought that one function of Heg is to anchor 
Ccm1 at the plasma membrane, where it suppresses RhoA signaling.  If the intracellular portion 
of Heg is cleaved and released from the membrane, it could downregulate Ccm1 activity by 
sequestering it in the cytoplasm.  Another possibility is that HegICD functions in the cell’s 
nucleus.  Ccm1 has functional nuclear localization signals (Zawistowski et al., 2005), but its 
nuclear activity is unknown.  It is possible that Ccm1 shuttles HegICD into the nucleus where it 
regulates gene expression, analogous to the nuclear function of the cleaved intracellular domain 
of Notch protein. 
 
The zebrafish orthologs of Heg and Ccm1 interact 
  We performed a yeast 2-hybrid screen using the highly conserved intracellular domain of 
Heg, HegICD, as bait against a library of clones isolated from embryonic zebrafish heart.  We 
performed  biochemical binding assays on 34 hits obtained in the screen and discovered that 
HegICD binds a Ccm1 fragment when the two are coexpressed in 293T cells and when they are 
expressed completely in vitro.  The latter experiment suggests that the interaction is direct, since 
the coupled in vitro transcription/translation reaction occurs in an environment lacking most 
cellular proteins.  The smallest ccm1 clone recovered from the screen contains just the C-
terminal, FERM-domain containing part of the Ccm1 protein, suggesting that it is this domain 
that interacts with Heg.  This finding was confirmed in experiments presented in Chapter 3 of 
this dissertation. 53 
 
  The finding that Ccm1 binds HegICD provides a window into the molecular mechanism 
behind the previously observed genetic interaction between the corresponding genes (Mably et 
al., 2006).  While this project was in progress, the biochemical interaction between Ccm1 and 
Heg was shown for their mammalian orthologs (Kleaveland et al., 2009).  Thus, the interaction 
between Ccm1 and Heg is conserved between zebrafish and mouse.  A recent study suggests that 
the function of the Heg-Ccm1 interaction is to recruit and anchor Ccm1 to the plasma membrane 
(Gingras et al., 2012).  Additional research will be required to fully understand how binding to 
Heg regulates the activity of Ccm1 and the downstream components of the Heg-CCM pathway. 
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Introduction 
 
The zebrafish is tremendously useful for the identification and characterization of genes 
that control heart development, as both heart morphology and its functional output, blood 
circulation, are easily visible in the transparent, externally developing embryo.  The embryonic 
zebrafish heart contains two chambers, one atrium and one ventricle, and each consists of two 
tissues: endocardium, which is a specialized endothelium that lines the inside of the heart, and 
the muscular myocardium surrounding it that generates the organ’s contractile force.  Three 
different mutants – santa (san), valentine (vtn), and heart of glass (heg) – exhibit the same 
striking phenotype: the heart and inflow tract are massively dilated, and although the heart beats, 
there is no blood circulation (Mably et al., 2006; Mably et al., 2003).  They die around 5 days 
post fertilization (dpf), which is a general feature of mutants that cannot form a functional 
cardiovascular system.  The genes disrupted in san, vtn, and heg mutants are ccm1, ccm2, and 
heg, respectively, and they are conserved across vertebrate species; their murine homologs 
Ccm1, Ccm2, and Heg1, respectively, are essential for normal cardiovascular development in 
mouse (Boulday et al., 2009; Kleaveland et al., 2009; Whitehead et al., 2009; Whitehead et al., 
2004). 
ccm1, ccm2, and heg interact genetically as components of a signaling system known as 
the Heart of glass-Cerebral Cavernous Malformation (Heg-CCM) pathway.  In zebrafish, slight 
knockdown of any of the three genes can drastically enhance heart phenotypes in embryos 
sensitized by a subphenotypic dose of morpholino against either of the other two (Mably et al., 
2006).  Similarly, the phenotype conferred by deletion of Heg1 in mouse is enhanced in animals 
haploinsufficient for Ccm2 (Kleaveland et al., 2009). CCM1, CCM2 and HEG1 proteins also 59 
 
interact biochemically.  Co-immunoprecipitation, FRET, and yeast 2-hybrid experiments have 
demonstrated physical interactions between human CCM1 and CCM2 (Zawistowski et al., 2005; 
Zhang et al., 2007).  CCM1 contains three NPXY/F motifs, ankyrin repeats, and a band 4.1, 
ezrin, radixin, moesin (FERM) domain.  CCM2 contains a phosphotyrosine binding (PTB) 
domain that is required for the CCM1-CCM2 interaction.  The NPXY/F motifs in CCM1 are 
targets of the PTB domain in CCM2, and disrupting these motifs singly or pairwise causes 
decreased CCM1-CCM2 binding (Zawistowski et al., 2005; Zhang et al., 2007).  HEG1 is a 
single pass transmembrane protein whose intracellular domain binds the CCM1-CCM2 complex 
(Kleaveland et al., 2009). 
There is strong evidence that the Heg-CCM pathway functions in the endothelium.  
Conditional mouse knockouts where Ccm2 is selectively deleted from the developing 
endothelium phenocopy the whole organism knockout, demonstrating that this pathway’s 
activity is required in the endothelium (Boulday et al., 2009; Whitehead et al., 2009).  in situ 
hybridization experiments in zebrafish embryos detect heg expression in the endocardium but not 
the myocardium, consistent with a model in which Heg-CCM signaling in the heart’s 
endothelium regulates heart morphology (Mably et al., 2003).  Adult mice heterozygous for 
Ccm2 exhibit vascular leakiness (Stockton et al., 2010) and hypersensitivity to the hemorrhagic 
effects of VEGF injection (Whitehead et al., 2009), and this phenotype is recapitulated in 
endothelial cell culture where loss of CCM1 or CCM2 causes increased monolayer permeability 
(Crose et al., 2009; Glading et al., 2007; Stockton et al., 2010; Whitehead et al., 2009).  These 
studies demonstrate that the Heg-CCM pathway is conserved across vertebrates and required in 
the endothelium for normal cardiovascular development and adult physiology. 60 
 
  The Heg-CCM pathway is so-named because mutations in the human CCM1 and CCM2 
genes cause vascular anomalies called cerebral cavernous malformations (CCMs) (Denier et al., 
2004; Laberge-le Couteulx et al., 1999; Liquori et al., 2003; Sahoo et al., 1999).  CCMs, which 
affect approximately 0.5% of the population, are malformations of the brain vasculature 
characterized by an expanded endothelial vessel that can result in headache, seizure, hemorrhage 
and death (Revencu and Vikkula, 2006).  CCMs can arise either spontaneously or as an 
autosomal dominant hereditary condition.  In addition to CCM1 and CCM2, a third gene, CCM3, 
also causes CCMs when mutated (Bergametti et al., 2005).  In overexpression studies, CCM3 
protein can bind CCM2 (Hilder et al., 2007; Li et al., 2010; Voss et al., 2007; Zheng et al., 2010), 
and knockdown of its two zebrafish homologs, ccm3a and ccm3b, affects heart development, 
though there are conflicting characterizations of this phenotype (Voss et al., 2009; Yoruk et al., 
2012; Zheng et al., 2010).  Since loss-of-function of ccm1 and ccm2 causes severe endothelial 
vessel dilation in both the embryonic zebrafish heart and the adult human brain, the zebrafish 
heart may provide insights into the genetic and cellular interactions that underlie human CCM 
disease. 
  Unlike other signaling pathways that have been studied extensively, the Heg-CCM 
pathway was discovered only recently and as a result remains incompletely understood.  We 
employed a straightforward bioinformatic approach to identify a novel gene with sequence 
identity to ccm2, which we have named ccm2-like (ccm2l).  Using morpholinos to knock down 
ccm2l in zebrafish embryos, we found that loss of ccm2l causes dilation of the atrium and inflow 
tract and a lack of blood circulation.  Slight reduction of ccm2l causes a dilated heart phenotype 
in embryos sensitized by a sub-phenotypic dose of ccm1 morpholino, defining ccm2l as an 
enhancer of the Heg-CCM pathway.  Injection of ccm2 mRNA can partially rescue 61 
 
cardiovascular defects in ccm2l morphants, suggesting that ccm2 and ccm2l have overlapping in 
vivo functions.  We demonstrate that Ccm2l protein binds Ccm1; moreover, we interrogate this 
interaction further to define the Ccm1 NPXY/F motif requirements for this interaction, which are 
different from those for Ccm1-Ccm2 binding.  Finally, we suggest that the human homolog of 
ccm2l, C20ORF160, may have relevance to human CCM disease. 
 
Materials and methods 
 
Zebrafish 
  All zebrafish husbandry procedures were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at Boston Children’s Hospital. 
Zebrafish embryos were raised in egg water at 28.5°C. Tubingen and (fli1:EGFP)
y1 (Lawson and 
Weinstein, 2002) zebrafish lines were used. For some experiments, embryos were incubated in 
0.003% 1-phenyl 2-thiourea (PTU) after 1 day of development to inhibit pigment formation. 
 
Expression analysis 
  in situ hybridization was performed as previously described (Mably et al., 2006; Mably et 
al., 2003). RT-PCR was performed either using the OneStep RT-PCR kit (Qiagen) on total RNA 
extracted from embryos by Trizol (Life Technologies) or by performing reverse transcription on 
total RNA using the QuantiTect Reverse Transcription Kit (Qiagen) followed by PCR. The 
following primers were used:  
ccm2: 5’-CGTCTATACCGAGTCCACCA-3’, 5’- AGGAGTCTTCACTGTAGATTGAG-3’. 
ccm2l: 5’- AGGTCAAGTTCCTGGGACAC-3’, 5’- CAGACAGACTGAGAATACAGTCC-3’. 62 
 
ccm1: 5’- CATAATAGGGAAGCGTGTTGTG-3’, 5’- GGAGGAGAAATGAGCACTGG-3’. 
gapdh: 5’- GGCAAACTGGTCATTGATGG-3 , 5’-CTTAATGTGAGCAGAAGCCT-3’. 
cmlc2: 5’-GGAGAGAAGCTCAATGGCACA-3’, 5’-GTCATTAGCAGCCTCTTGAACTCA-
3’. 
insulin: 5’-GTG GAT CTC ATC TGG TCG ATG C-3’, 5’-AGG AGG AAG GAA ACC CAG 
AAG G-3’, as previously described (Burns and MacRae, 2006). 
β-actin: 5’-GCTGTTTTCCCCTCCATTGTT-3’, 5’-TCCCATGCCAACCATCACT-3’. 
  For comparison of gene expression in heart and whole embryo, embryonic heart 
purification was performed as previously described (Burns and MacRae, 2006). 
 
Embryo microinjection 
  Morpholinos, designed by Gene Tools, LLC, were diluted in water to make stock 
solutions and further diluted in water containing a final concentration of 0.1% phenol red for 
injections.  Embryos were injected in the yolk with 1-2 nL of diluted morpholino no later than 
the 2-cell stage using a PLI-100 pico-injector (Harvard Instruments) and subsequently raised at 
28.5 °C.  The following morpholinos were used: 
ccm1: 5’-GCTTTATTTCACCTCACCTCATAGG-3’ 
ccm2l: MO e4i4: 5’-ACATTTCACTCTTACTAACCAGTTT-3', 
  MO e2i2: 5’-TCAGACTAGACCTTGACCTCCTTCT-3’. 
ccm2: 5’-GAAGCTGAGTAATACCTTAACTTCC-3’. 
Standard control MO: 5'-CCTCTTACCTCAGTTACAATTTATA-3'. 
  In experiments to characterize the ccm2l knockdown phenotype, we injected 1.0 pMol 
MO e4i4 or 0.3 pMol MO e2i2.  For enhancer experiments, pairwise combinations of 63 
 
morpholino were injected as single solutions.  For experiments with either MO e4i4 or MO e2i2, 
each 1 nL injection volume contained 0.01 pMol ccm1 MO + 0.05 pMol ccm2l MO, 0.01 pMol 
ccm1 MO + 0.05 pMol standard control MO, or 0.01 pMol standard control MO + 0.05 pMol 
ccm2l MO.  The experimenter was blinded to these solutions prior to injection.  For rescue 
experiments, embryos were first injected with morpholino (0.3 pMol MO e2i2 or 1.0 pMol MO 
e4i4), randomly sorted into three groups, and then injected a second time with 0.1 ng ccm2
wt 
mRNA or 0.1 ng ccm2
m201 mRNA.  (The third group was left singly injected.)  The experimenter 
was blinded to these treatments prior to assaying phenotypes at 52 hpf. 
  Morpholinos against ccm1 and ccm2 were previously validated (Mably et al., 2006).  
To validate morpholinos against ccm2l, total RNA was isolated from embryos injected with 
morpholino and uninjected control embryos using Trizol reagent (Life Technologies) as per the 
manufacturer’s instructions.  The RNA was then subjected to reverse transcription PCR (RT-
PCR) using the OneStep RT-PCR kit (Qiagen) with exonic primers flanking the exon-intron 
boundary targeted by the morpholino.  RT-PCR products were visualized by SYBR safe (Life 
Technologies) on an agarose gel. The following PCR primers were used: 
ccm2l: 5’-TGGACTATGATCCCAAGCGAACCA-3’, 5’- 
GGGTTCAGGGAACAGGACACCCA-3’. 
ccm2: 5’- ATGGAGGAGGATGTAAAGAA-3’, 5’- TCAGGTATCCAGGAACTGAGG -3’. 
 The ccm2l MO e2i2 and uninjected PCR products were subcloned into the PCRII-TOPO vector 
(Life Technologies) and sequenced. 
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  Capped RNA was transcribed in vitro from linearized pCS2-ccm2, pCS2-ccm2
m201, and 
pXT7-ccm2le2i2 templates using the mMessage mMachine SP6 or T7 Ultra kits (Life 
Technologies) and purified using the MEGAclear kit (Life Technologies).  As the last step of the 
purification, RNA was eluted in water and subsequently diluted in water and phenol red (final 
concentration of 0.1%) prior to injection. 
 
Cloning and plasmid generation 
  The generation of pCMV-Myc-heg was described in chapter 2 of this dissertation.  ccm2l  
was cloned from cDNA reverse transcribed from total RNA isolated from 2 dpf zebrafish 
embryos.  The following forward and reverse primers were designed with an EcoRI site and a 
XhoI site, respectively, to allow for subcloning of the PCR product into pCMV-HA (Clontech):  
5’- GATCGAATTCAAATGGACTATGATCCCAAGCG-3’,  
5’- GATCCTCGAGTCACAAGTAATAATCCTCCTC-3’.  
pCMV-HA-ccm2 was generated by performing PCR on a previously described pCS2-
ccm2 template (Mably et al., 2006) with primers containing EcoRI and XhoI restriction sites 
followed by digestion and ligation into pCMV-HA.  The following primers were used:  
5’-GATCGAATTCAAATGGAGGAGGATGTAAAGAAAG-3’,  
5’-GATCCTCGAGTCAAGATGGCACGCCGTCTTG-3’.  
Ccm1 deletion constructs were generated by performing PCR on full-length ccm1 cDNA 
template with primers containing EcoRI or XhoI restriction sites and subcloning PCR fragments 
into pCMV-tag2b (Stratagene).  The following PCR primers were used:  
pCMVtag2b-ccm1: 
5’-GATCGAATTCATGATGGGAAACCAAGAGCTAG-3’,  65 
 
5’-GATCCTCGAGTTACCCATACGCATATTTATC-3’.  
pCMVtag2b-ccm1∆NPXY/F:  
5’-GGAATTCAAATGGCAGCACAGCATGACC-3’,  
5’-ACCGCTCGAGTTACCCATACGCATAT -3’.  
pCMVtag2b-ccm1∆NPXY/F-ANK:  
5’-GGAATTCTGGGAGGAAACCGTGAATCTC-3’,  
5’- ACCGCTCGAGTTACCCATACGCATAT -3’.  
pCMVtag2b-ccm1∆FERM:  
5’-GGAATTCATGGGAAACCAAGAGCTAGAG-3’,  
5’-ACCGCTCGAGGAGATTCACGGTTTCCTC-3’.  
  FLAG-ccm1
ty219c and FLAG-ccm1
m775 were generated using the same primers and vector 
as pCMVtag2b-ccm1, but with PCR templates containing the appropriate ccm1 alleles.  
Point mutations were inserted in pCMVtag2b-ccm1 using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene).  The following primers were used: 
Y193A:  
5'-GTGAGTAACCCGGCGGCCGCAGTGGAGAAGCA-3,  
5'-TGCTTCTCCACTGCGGCCGCCGGGTTACTCAC-3'.  
Y231A:  
5'-CATCCAGAACCCGCTGGCCGGCTCAGATCTGCAG-3’, 
5'-CTGCAGATCTGAGCCGGCCAGCGGGTTCTGGATG-3'.  
Y249A,F250A:  
5’-ACAGAGTGGACAAAGTCATCATCAACCCTGCCGCTGGCTTGGGAGCTCC-3,  
5’- GGAGCTCCCAAGCCAGCGGCAGGGTTGATGATGACTTTGTCCACTCTGT-3’.  66 
 
pXT7-ccm2le2i2 was generated by shuttling the MO e2i2 induced RT-PCR product (i.e. 
the upper band containing an intronic insertion) from PCRII-TOPO to pXT7. 
 
Cell culture and western blotting 
  Transfections, co-immunoprecipitation, and western blotting were performed as 
described in chapter 2 of this dissertation.  Antibodies against Heg, FLAG, and HA were used as 
described. 
 
Microscopy 
  Images of live embryos were taken and processed as described in chapter 2.  
 
Results 
 
ccm2l is a novel, conserved gene expressed during embryonic development 
  To identify potential homologs of genes in the Heg-CCM pathway, we queried the NCBI 
databases for entries with sequence identity to Heg-CCM genes using both BLASTp and 
BLASTx algorithms.  We identified a protein bearing 43% identity to Ccm2, which we have 
named Ccm2-like (Ccm2l) (Figure 3.1A).  The coding sequence of ccm2l contains 1842 
nucleotides and the corresponding protein has 613 amino acids.  The only domain in Ccm2l 
readily predicted by the protein’s primary sequence is a Pleckstrin-homology (PH) domain-like 
region comprised of amino acids 45-146 (Gough et al., 2001).  The PH-like domain superfamily 
includes PTB domains; since the PH-like domain in Ccm2l has high identity to the PTB domain 
of Ccm2, we consider the PH-like domain to be a putative PTB domain.  Ccm2l and Ccm2 67 
 
contain regions of high identity not only in their PTB domains, but also in their C-terminal ends 
(Figure 3.1A,B).  We amplified ccm2l from RNA isolated from 2-day old embryos using primers 
corresponding to the 5’ and 3’ ends of the coding region of the transcript.  Sequencing of our 
clone revealed that it matches the full-length transcript predicted by the Ensembl Genome 
Browser.  ccm2l homologs are found in other vertebrate species, including human, where it is 
called C20ORF160. 
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Figure 3.1 (Continued).  Sequence and expression analysis of ccm2l.  (A) Alignment of 
Ccm2l and Ccm2 protein sequences.  Black residues are identical and gray residues are similar.  
(B) Schematic comparing the domain structures of Ccm2l and Ccm2. The N-terminal region of 
Ccm2l contains a putative PTB domain with high identity to the PTB domain of Ccm2.  The two 
proteins also have regions of high identity at their C-termini.  (C) RT-PCR showing expression 
of ccm2, ccm2l, ccm1 and the positive control gapdh at five embryonic stages.  All four genes 
are expressed at all five time points tested between 0 and 48 hpf.  Water (w) is included as a 
negative control.  (D) RT-PCR comparing expression of ccm2l and ccm1 in whole embryos (e) 
and purified embryonic hearts (h) at 52 hpf.  Both genes are expressed in the heart, with the ratio 
of heart expression to whole embryo expression much higher for ccm2l.  RT-PCR for the heart-
specific marker cardiac myosin light chain (cmlc2) and for a transcript absent from the heart, 
insulin (ins), demonstrate the quality of the heart tissue purification.  (E) in situ hybridization 
analysis of ccm2l expression.  In 30 hpf embryos, ccm2l expression is detected in the posterior 
end of the embryo in the presumptive notochord (arrowheads) and the tissue ventral to it 
(arrows).  Embryos treated with sense probe as a negative control lack staining in these domains.  
PH, Pleckstrin-homology superfamily; PTB, phosphotyrosine binding domain. 
 
  We performed RT-PCR and in situ hybridization to analyze when and where in the 
embryo ccm2l is expressed.  By RT-PCR we found that transcripts for ccm2l, like ccm1 and 
ccm2, are present at all time points we tested between fertilization and 48 hours post fertilization 
(hpf) (Figure 3.1C).  The presence of transcripts at the zygote stage implies a maternal 
contribution of these messages.  Because the Heg-CCM pathway functions in heart development, 
we mechanically purified 52 hpf zebrafish embryonic hearts and performed RT-PCR for ccm1 
and ccm2l expression, and we found that both genes are expressed in the heart (Figure 3.1D). 
Next we performed in situ hybridization for ccm2l.  We found that at 30 hpf, ccm2l is 
detectable in the presumptive notochord at the posterior end of the embryo and the tissue ventral 
to it; the corresponding negative control sense probe does not produce any signal in these 
domains (Figure 3.1E).  This expression pattern shares features with those of ccm1 and ccm2; it 
has previously been shown that ccm1 is expressed in the notochord at 48 hpf and ccm2 is 
expressed in the intermediate cell mass ventral to the notochord at 28 hpf (Mably et al., 2006).  70 
 
The mouse homolog of ccm2l has previously been shown to be enriched in embryonic-stem cell 
derived CD31
+ endothelial-like cells (Mariappan et al., 2009). 
 
ccm2l is required for heart development 
  To characterize the role of ccm2l in zebrafish development, we employed a morpholino 
loss-of-function strategy.  First, we designed a morpholino, MO e4i4, to bind an exon-intron 
junction in the ccm2l pre-mRNA.  Microinjection of embryos with this morpholino caused a 
heart phenotype with little overall toxicity, but surprisingly, we could not detect any changes to 
the ccm2l transcript when we performed RT-PCR using primers targeted to neighboring exons.  
Others have reported the same phenomenon and suggested that splice site morpholinos may in 
some cases prevent efficient translation (Schottenfeld et al., 2007).  Alternatively, the 
morpholino-induced RNA product may be subject to rapid nonsense-mediated decay.  We 
designed a second splice site morpholino, MO e2i2, and found that it confers a similar phenotype 
to MO e4i4.  RT-PCR followed by sequencing demonstrated that MO e2i2 increases the amount 
of an endogenous alternative transcript at the expense of the expected transcript (Figure 3.2A).  
Sequencing revealed that the alternative transcript contains an intronic inclusion with a 
premature stop codon (Figure 3.2B); thus, MO e2i2 appears to cause a shift from normal Ccm2l 
protein to a severely 
truncated isoform.  Splicing of ccm2 at the homologous exon-intron junction is not affected 
(Figure 3.3). 71 
 
 
Figure 3.2.  ccm2l morphants exhibit heart and inflow tract defects.  (A) Injection of MO 
e2i2 increases production of an endogenous alternatively spliced product (arrow) at the expense 
of the presumptive functional transcript (arrowhead).  (B) Sequencing reveals that the 
alternatively spliced ccm2l mRNA, which is observed at increased levels in embryos injected 
with MO e2i2, incorporates intron 2, leading to an in-frame stop codon.  (C and F) Uninjected 
embryos have compact heart chambers and narrow inflow tracts.  (D,E,G,H) Embryos injected at 
the one-cell stage with 0.3 pMol MO e2i2 (D and G) or 1.0 pMol MO e4i4 (E and H) exhibit 
dilation of the atrium and inflow tract.  Embryos injected with MO e2i2 often have a curved 
body axis.  All images are taken from a lateral perspective with anterior to the left. a, atrium; i.t., 
inflow tract. 
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Figure 3.3.  MO e2i2 affects splicing of ccm2l but not ccm2.  RT-PCR using primers flanking 
the exon 2-intron 2 junction of ccm2l demonstrates a shift from the normally spliced transcript 
(arrowhead) to an alternative transcript (arrow) in embryos injected with MO e2i2.  In contrast, 
primers flanking the exon 2-intron 2 junction of ccm2 detect no difference in transcript size 
between uninjected embryos and embryos injected with MO e2i2. 
 
Loss-of-function of ccm2 in zebrafish causes a massively dilated heart phenotype (Mably 
et al., 2006).  We began our phenotypic study of ccm2l by asking whether its knockdown affects 
heart development.  At 52 hpf, uninjected embryos display compact heart chambers, a narrow 
inflow tract, and robust circulation (Figure 3.2C,F).  In contrast, we observe dilation of the 
atrium in 25-50% of the embryos injected with MO e2i2 (Figure 3.2D,G).  This heart phenotype 
is coincident with dilation of the inflow tract and in some embryos a complete cessation of blood 
circulation despite a rhythmic heart beat.  Experiments with MO e2i2 require a relatively low 
dose of morpholino, as higher doses cause global developmental defects.  Even at low doses, 
typically some embryos had to be excluded from analysis due to global defects.  Embryos 
injected with MO e4i4 exhibit a phenotype similar to those injected with MO e2i2, consisting of 
dilated inflow tracts often accompanied by dilated atria at 2 dpf (Figure 3.2E,H), at a lower 
penetrance of 18%.  Heart phenotypes caused by either ccm2l morpholino are less severe than 
those observed in san, vtn, and heg mutants; it is unknown whether this distinction is biologically 
relevant or simply due to incomplete ccm2l knockdown. 73 
 
  Because our RT-PCR data show that MO e2i2 can cause heart phenotypes even though a 
substantial amount of normal transcript remains in the embryo, we considered the possibility that 
the inclusion of intron 2 generates a dominant negative protein.  To test this hypothesis, we 
injected mRNA containing the open reading frame of the morpholino-induced transcript and 
found that although a small number of embryos had heart or circulatory defects, the majority 
appeared to have morphologically normal hearts and blood circulation (Figure 3.4A-D).  Thus, 
we favor the hypothesis that MO e2i2 does not generate a protein with dominant negative 
activity, but rather exerts a phenotype by incompletely knocking down levels of Ccm2l.  
Similarly, we found that morpholino against ccm2 can confer an intermediate heart phenotype 
when injected at doses that allow for a substantial amount of normal transcript to endure (Figure 
3.4E-K). 
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Figure 3.4.  MO e2i2 does not appear to generate a dominant negative product.  Embryos 
were injected with mRNA corresponding to the upper band in Figure 3.2a.  This mRNA 
contained exon 1, exon 2, intron 2 (containing a stop codon), and part of exon 3 from ccm2l.  (A) 
The majority of embryos (32/44) injected with this mRNA had a morphologically normal heart 
and circulation.  (B) Five of 44 embryos had a morphologically normal heart and no circulation.  
(C) Four of 44 embryos had an enlarged heart and no circulation.  (D) Three of 44 embryos 
exhibited cyclopia, an effect often seen with mRNA overexpression.  (E-J) Embryos were 
injected with varying amounts of ccm2 MO and grouped at 2 dpf as either wildtype, 
intermediate, or severe.  (K) RNA was isolated and subjected to RT-PCR using primers 
corresponding to the exons flanking the morpholino target site.  The upper band (arrow, 465 bp) 
represents normal ccm2 transcript, while the lower band (arrowhead, 288 bp) represents aberrant 
ccm2 transcript lacking exon 2.  Embryos in which a substantial amount of ccm2 transcript is 
unaffected can still exhibit a phenotype (see 100 µM, intermediate).  RT, reverse transcriptase; 
wt, wildtype; inter., intermediate. 
 
 
  Next, we examined the effects of morpholino-mediated ccm2l knockdown on the 
embryonic vasculature using the (fli1:EGFP)
y1 transgenic line, in which all endothelial cells are 75 
 
labeled with EGFP (Lawson and Weinstein, 2002).  We compared the morphology of several 
vessels in embryos injected with a standard control morpholino (cont MO) and those injected 
with MO e4i4; we chose this morpholino for analysis because its low toxicity prevents secondary 
vascular phenotypes caused by global developmental defects.  We examined the endocardium, 
common cardinal vein (CCV), and mesencephalic veins (MsVs) at 52 hpf, the intersegmental 
veins (ISVs) at 58 hpf and the subintestinal veins (SIVs) at 72 hpf.  For this analysis, we selected 
embryos displaying heart and inflow tract defects.  As expected, the morphant endocardium 
appears dilated compared to embryos injected with cont MO (Figure 3.5A,B).  The CCVs in 
affected embryos are generally normal (Figure 3.5C,D).  (We have observed some CCVs 
exhibiting developmental delay at 2 dpf that appear normal by 3 dpf.)  We observe relatively 
minor defects in the ISVs and SIVs; the ISVs in affected embryos are normally patterned but a 
small number of vessels fail to lumenize (Figure 3.5E,F), and SIVs frequently display an 
irregular growth pattern (Figure 3.5G,H).  These defects may be explained by a reduction in 
blood circulation, as silent heart (sih) mutants, which completely lack blood flow owing to a 
defect in cardiac contractility, exhibit more severe versions of those phenotypes (Hogan et al., 
2008; Mably and Childs, 2010).  It was recently reported that combined knockdown of ccm3a 
and ccm3b, but not ccm1 or ccm2, causes extreme dilation of the MsVs in zebrafish, a phenotype 
of particular interest because of its similarity to dilated brain vessels in patients with CCM 
disease (Yoruk et al., 2012).  We observed that MsVs in cont MO-injected embryos are 
approximately the same width as those in MO e4i4-injected embryos (Figure 3.5I-K).  Taken 
together, these data suggest that ccm2l function may be more crucial for development of the 
endocardium than for the other major vessels we investigated. 
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Figure 3.5.  Effects of ccm2l disruption on embryonic vasculature.  (A and B) At 52 hpf, 
control embryos have an appropriately constricted endocardium, while ccm2l morphants exhibit 
endocardial dilation.  (Arrows show lumen diameter).  (C and D) Morphology of the CCV at 52 
hpf is generally normal in ccm2l morphants.  (E and F) At 58 hpf, ISVs are mostly insensitive to 
ccm2l loss-of-function, although some affected embryos have ISVs that are not fully dilated 
(arrowhead).  (G and H) At 72 hpf, SIVs in affected embryos are frequently mispatterned.  (I -K) 
At 52 hpf, MsVs are approximately the same width in control embryos and affected embryos 
(arrowheads).  A and B are 20x magnification; C-J are 10x magnification.  A-F are taken from a 
lateral perspective with anterior to the left; G and H are dorsal images with anterior to the right.  
I and J are taken from a dorsal perspective with the anterior end tilted upward.  In K, error bars 
represent standard error.  Cont, standard control morpholino. 
 
ccm2l is an enhancer of the Heg-CCM pathway 
  The heart phenotype conferred by ccm2l morpholino injection is consistent with a role for 
ccm2l  in the Heg-CCM pathway.  To directly test whether there is a genetic interaction between 
ccm2l and the Heg-CCM pathway, we undertook a morpholino co-injection approach that has 77 
 
previously been used to demonstrate genetic interactions among ccm1, ccm2, and heg (Mably et 
al., 2006).  We determined subphenotypic doses of ccm2l and ccm1 morpholinos and injected 
them either together or individually with control morpholino.  At 52 hpf, we assayed embryos for 
the dilated heart phenotype we observe in heg, ccm1, and ccm2 mutants.  Embryos were scored 
under light microscopy as either wildtype, intermediate, or severe.  Wildtype embryos have heart 
morphology and blood circulation comparable to uninjected embryos; intermediate embryos 
have moderately dilated hearts and inflow tracks and often sluggish circulation; and severe 
embryos have largely dilated hearts and inflow tracts and completely lack circulation of red 
blood cells (Figure 3.6A).  Due to the somewhat subjective nature of this rubric and the extreme 
sensitivity of the experiment’s outcome to the precise injection volume each embryo receives, 
the morpholino solutions were blinded to the experimenter prior to injection and revealed after 
all embryos were scored. 
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Figure 3.6.  ccm2l interacts genetically with the Heg-CCM pathway.  (A-C) For enhancer 
experiments, embryos were injected with low doses of control morpholino, ccm1 morpholino and 
ccm2l morpholino in pairwise combinations and assayed at 52 hpf for heart morphology and 
function.  (A) Embryos classified as “wildtype” have a heart and inflow tract comparable to 
uninjected embryos and strong blood circulation.  “Intermediate” embryos exhibit moderate 
dilation of the atrium and inflow tract but maintain some level of blood circulation.  “Severe” 
embryos have extreme dilation of the heart and inflow tract and lack blood circulation.  (B and 
C) Compared to a control morpholino with no predicted cellular targets, MO e2i2 and MO e4i4 
both increase the proportion of moderate and severe phenotypes in embryos sensitized with ccm1 
morpholino.  Images of embryos were taken at 10x magnification from a lateral perspective with 
anterior to the left.  Graphs represent data pooled from at least three independent experiments. 
For each group, n>98 embryos.  (D,E) For rescue experiments, embryos were injected with 
ccm2l morpholino and subsequently injected with mRNA transcribed in vitro from either 
wildtype ccm2 cDNA (ccm2+) or from cDNA corresponding to the ccm2 mutant allele 
ccm2
m201(ccm2-).  (D) ccm2
wt RNA rescued circulation in a significant proportion of embryos 
injected with MO e2i2, while ccm2
m201 RNA did not.  (E) Similarly, ccm2
wt RNA but not 
ccm2
m201 RNA rescued heart and inflow tract morphology in a significant proportion of embryos 
injected with MO e4i4.  Embryos exhibiting an enlarged inflow tract and/or enlarged atrium 
were labeled as “dilated inflow tract/atrium.”  Graphs represent data pooled from three  79 
 
(Figure 3.6, continued) independent experiments.  For each group, n>130 embryos. p-values are 
calculated from a 2x2 contingency table using Fisher’s exact test.  n.s., not significant. 
 
We found that both ccm2l morpholinos enhance the dilated heart phenotype in embryos 
sensitized with ccm1 morpholino.  In experiments with MO e2i2, 49% of embryos receiving 
ccm1 and ccm2l morpholinos had either intermediate or severe phenotypes, while only 15% of 
embryos that received ccm1 morpholino with the equivalent amount of control morpholino had 
those phenotypes.  Just 2% of embryos receiving MO e2i2 with control morpholino had a heart 
phenotype (Figure 3.6B).  In experiments with MO e4i4, 28% of embryos receiving ccm1 and 
ccm2l morpholinos had either intermediate or severe phenotypes, while only 4% of embryos that 
received ccm1 morpholino with the equivalent amount of control morpholino had those 
phenotypes.  No embryos injected with MO e4i4 and control morpholino developed abnormal 
heart phenotypes (Figure 3.6C).  We conclude that ccm2l is an enhancer of the Heg-CCM heart 
phenotype. 
 
 ccm2 overexpression partially rescues ccm2l morphant phenotypes 
 Due to the high degree of homology between Ccm2 and Ccm2l, our observation that 
their knockdown confers similar phenotypes, and our finding that ccm2l knockdown can enhance 
the heart phenotype in ccm1 morpholino-sensitized embryos, we hypothesized that ccm2 and 
ccm2l have overlapping in vivo functions.  To test this hypothesis, we attempted to rescue ccm2l 
morpholino-injected embryos with synthetic ccm2 mRNA.  Since the severity of phenotype 
caused by our ccm2l morpholinos is sensitive to the volume of morpholino received by the 
embryo, we used a double-injection approach to insure that all groups, on average, received the 
same amount of ccm2l morpholino.  First we injected a large pool of embryos with ccm2l 80 
 
morpholino and then randomly divided the pool into three groups.  One group was re-injected 
with wildtype ccm2 mRNA, the second group was re-injected with ccm2 mRNA transcribed 
from a loss-of-function allele isolated from the zebrafish mutant vtn
m201 as a negative control, and 
the third group did not receive a second injection.  At 52 hpf, embryos were assayed in a blind 
fashion. 
In experiments with MO e2i2, we used circulation down the trunk of the embryo as a 
functional readout for cardiovascular rescue.  Embryos injected with only MO e2i2 or MO e2i2 
and ccm2
m201 mRNA had blood circulation at rates of 53% and 52%, respectively.  In contrast, 
embryos that received MO e2i2 and ccm2
wt mRNA had circulation at a frequency of 73% (Figure 
3.6D). We observed the same trend with MO e4i4.  In rescue experiments with this morpholino, 
we scored embryos by heart and inflow tract morphology rather than blood circulation because 
MO e4i4 exhibits low penetrance and rarely causes circulatory block.  We found that 82% and 
85% of embryos injected with only MO e4i4 or MO e4i4 and ccm2
m201 mRNA, respectively, had 
normal hearts and inflow tracts.  However, 91% of embryos that received MO e4i4 and ccm2
wt 
mRNA had normal hearts and inflow tracts (Figure 3.6E).  For both morpholinos, rescue 
achieved by ccm2
wt mRNA was statistically significant, whereas any rescue achieved by 
ccm2
m201 mRNA was not. 
   
Ccm2l binds Ccm1 
Next, we sought a molecular explanation for our phenotypic results linking ccm2l to the 
Heg-CCM pathway.  Based on its homology to Ccm2, which is known to bind Ccm1 
(Zawistowski et al., 2005; Zhang et al., 2007), we hypothesized that Ccm2l binds Ccm1 as well.  
To test this hypothesis, we overexpressed epitope-tagged versions of Ccm1 and Ccm2l in 293T 81 
 
cells, and then immunoprecipitated Ccm1 and blotted for Ccm2l.  As a positive control, we 
performed the same experiment with Ccm1 and Ccm2.  We found that both HA-ccm2 and HA-
ccm2l bind FLAG-ccm1 (Figure 3.7).  Since we previously showed that ccm1 and ccm2l are both 
expressed in the heart (Figure 3.1D), this interaction in cell culture likely recapitulates an 
endogenous interaction. 82 
 
 
 
Figure 3.7 
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Figure 3.7 (Continued).  Biochemical interactions among proteins of the Heg-CCM 
pathway.  (A) Schematic of all Ccm1 constructs used for co-immunoprecipitation experiments 
and a summary of binding results.  (B) FLAG-ccm1 and FLAG-ccm1∆FERM co-
immunoprecipitate HA-ccm2 and HA-ccm2l, while the N-terminal Ccm1 deletion proteins do 
not bind HA-ccm2 and HA-ccm2l.  In contrast, FLAG-ccm1∆FERM does not co-
immunoprecipitate Heg, while the N-terminal Ccm1 deletion proteins do.  (C) HA-ccm2 binding 
to FLAG-ccm1 is severely weakened by mutation of Ccm1’s two NPXY motifs and further 
disrupted by mutations in the NPXF motif.  The strength of the interaction between HA-ccm2l 
and FLAG-ccm1 is unaffected by mutation of Ccm1’s NPXY motifs but is severely diminished 
when all three NPXY/F motifs are mutated.  Heg-Ccm1 interactions appear unaffected by 
mutation of either two or all three NPXY/F motifs in Ccm1.  (D) The mutant Ccm1 proteins 
FLAG-ccm1
ty219c and FLAG-ccm1
m775 bind HA-ccm2 and HA-ccm2l as well as wildtype FLAG-
ccm1 does, but they do not bind Heg. 
 
To further define the interaction between Ccm2l and Ccm1, we performed a deletion 
analysis to determine which domains of Ccm1 bind Ccm2l.  We generated two N-terminal Ccm1 
deletion constructs, one lacking the three NPXY/F motifs and the other lacking these motifs as 
well as the ankyrin repeats, and a C-terminal deletion construct lacking the FERM domain.  All 
these constructs contain an N-terminal FLAG tag (Figure 3.7A).  In the 293T cell overexpression 
system, we found that protein generated from the C-terminal deletion construct, FLAG- 
ccm1∆FERM, efficiently bound HA-ccm2l.  In contrast, FLAG-ccm1∆NPXY/F and FLAG-
ccm1∆NPXY/F-ANK did not bind HA-ccm2l (Figure 3.7B).  We observed the same result for 
Ccm1 binding to Ccm2 (Figure 3.7B), consistent with others’ work demonstrating an interaction 
between the N-terminal domain of human CCM1 and CCM2 (Zhang et al., 2007). 
We also performed the same deletion analysis to determine which domains of Ccm1 are 
necessary to bind Heg, using a polyclonal antibody against Heg.  We found that Ccm1 proteins 
with N-terminal deletions efficiently co-immunoprecipitate Heg.  In contrast, Ccm1 protein 
lacking the FERM domain does not (Figure 3.7B).  We saw the same result when we replaced 
full-length Heg with Heg protein lacking its entire extracellular domain (Figure 3.8).  Thus, the 
C-terminal FERM domain-containing region of Ccm1 is necessary and sufficient to bind the 84 
 
intracellular domain of Heg.  These results are in contrast to Ccm1’s interactions with Ccm2 and 
Ccm2l, for which the C-terminal region of Ccm1 is dispensable but the N-terminal region is 
essential.  Consistent with our studies of the zebrafish proteins, it was recently shown that human 
HEG1 interacts with the FERM domain of CCM1 (Gingras et al., 2012). 
 
 
Figure 3.8.  The FERM domain of Ccm1 is necessary and sufficient to bind the 
intracellular domain of Heg.  FLAG-tagged Ccm1 deletion constructs were cotransfected with 
a HA-tagged construct corresponding to the intracellular domain of Heg (HA-HegICD).  Protein 
complexes were immunoprecipitated with FLAG antibody and blotted for FLAG and HA.  As 
with full-length Heg, the FERM domain of Ccm1 is necessary and sufficient to co-
immunoprecipitate HA-HegICD. 
 
  The N-terminal region of zebrafish Ccm1 contains two NPXY motifs and one NPXF 
motif.  Since Ccm2l contains a putative PTB domain, we hypothesized that the Ccm2l-Ccm1 
interaction requires these motifs.  To test this hypothesis, we generated two mutant ccm1 85 
 
constructs (Figure 3.7A).  In the first, FLAG-ccm1-AA, we altered both NPXY motifs by 
mutating the tyrosine residue in each to alanine.  The second, FLAG-ccm1-AAAA, contains 
those mutations as well as two mutations in the NPXF motif.  We doubly mutated the NPXF 
motif because the residue occupying the third position (“X”) is a tyrosine.  Since either the 
tyrosine or the phenylalanine could be mediating a protein binding interaction, we converted 
both to alanine.  We found that FLAG-ccm1-AA binds HA-ccm2l as strongly as wildtype 
FLAG-ccm1, but binding of FLAG-ccm1-AAAA to HA-ccm2l is extremely diminished.  In 
contrast, we found that the interaction between FLAG-ccm1-AA and HA-ccm2 is diminished 
relative to the interaction between wildtype FLAG-ccm1 and HA-ccm2, and that the interaction 
between FLAG-ccm1-AAAA and HA-ccm2 is weaker still (Figure 3.7C).  Thus, the NPXY 
motifs of Ccm1 are required for strong binding of Ccm1 to Ccm2 but dispensable for binding of 
Ccm1 to Ccm2l.  As a control, we also tested the interactions between Ccm1 NPXY/F mutant 
proteins and Heg.  Consistent with our finding that the N-terminal region of Ccm1 is not required 
for binding to Heg, FLAG-ccm1-AA and FLAG-ccm1-AAAA bind Heg as strongly as wildtype 
FLAG-Ccm1 (Figure 3.7C). 
Finally, we sought to determine whether the defective Ccm1 proteins produced by our 
san mutant fish are capable of binding Ccm2l, Ccm2, and Heg.  The mutant alleles ccm1
ty219c and 
ccm1
m775 have a point mutation and deletion, respectively, within the 3’ end of the mRNA that 
are predicted to disrupt the FERM domain in both cases (Mably et al., 2006) (Figure 3.7A).  We 
subcloned these mutant alleles into expression plasmids with FLAG tags and found that both 
produce proteins that can bind Ccm2 and Ccm2l.  However, neither mutant Ccm1 protein can 
bind Heg (Figure 3.7D).  The FERM domain of Ccm1 has been shown to bind the small GTPase 
RAP1 and membrane proteins such as β-Catenin (Glading et al., 2007; Liu et al., 2011).  We 86 
 
hypothesize that the san
m775 and san
ty219c mutant embryos exhibit their heart phenotype owing to 
an inability of Ccm1 to bind these proteins as well as Heg, rather than an inability to bind Ccm2 
and Ccm2l. 
 
Discussion 
 
ccm2l is required for normal cardiovascular development 
  We identified Ccm2l as a novel, conserved protein bearing considerable identity to 
Ccm2, and performed a loss-of-function analysis using two nonoverlapping morpholinos 
targeted to exon-intron junctions in the ccm2l pre-mRNA.  ccm2l morphants exhibit dilation of 
the atrium and inflow tract and in severely affected embryos reduced or absent blood circulation.  
The heart and inflow tract phenotypes we observe in ccm2l morphants are reminiscent of but less 
severe than the phenotypes in san, vtn, and heg mutants. ccm2l morphants may have a more mild 
heart phenotype than these mutants because ccm2l has a more subtle role in heart development, 
or the difference could simply be a reflection of incomplete ccm2l knockdown.  In the future, 
generation of a ccm2l null mutant will be crucial to resolving this ambiguity.  
  Morpholino disruption of ccm2l also confers subtle defects in other regions of the 
vasculature; in ccm2l morphants, a small number of ISVs fail to lumenize, and many SIVs have 
unusual growth patterns.  The ISV and SIV phenotypes may be due to compromised blood flow 
in the embryo, since sih mutants, which have no blood circulation, have more severe versions of 
these phenotypes (Hogan et al., 2008; Mably and Childs, 2010).  While we favor the 
interpretation that the primary function of ccm2l is to regulate heart morphology and the extra-
cardiac vascular defects in ccm2l morphants are due to reduced blood circulation caused by heart 87 
 
dilation, we cannot yet rule out the possibility that ccm2l functions directly in vessels outside the 
heart. 
Our in situ hybridization data showing ccm2l expression in the notochord and ICM do not 
correlate with our findings that ccm2l is essential for heart development.  While it is possible that 
ccm2l could regulate heart morphogenesis from a distant location, we believe the more likely 
explanation for the discrepancy between expression pattern and phenotype is that our in situ 
hybridization protocol is insufficiently sensitive to detect ccm2l in the heart.  In support of this 
reasoning, we can detect by RT-PCR ccm2l transcript in hearts dissociated from 2 dpf embryos.  
The case with ccm1 is similar; ccm1 is required for heart development and is detectable in 
purified hearts by RT-PCR, yet we have been unable to detect ccm1 expression in the embryonic 
heart by in situ hybridization.  Based on our phenotypic and RT-PCR data, as well as the 
literature in the field, we think that the Heg-CCM pathway, including ccm2l, has a tissue-
autonomous function in the heart’s endocardium.  Tissue-specific manipulations of the Heg-
CCM pathway in zebrafish will be required to demonstrate this. 
 
ccm2l is a component of the Heg-CCM pathway 
  We conclude that ccm2l is a component of the Heg-CCM pathway based on four lines of 
evidence.  First, disruption of ccm2l by morpholino injection causes dilation of the atrium and 
inflow tract.  These phenotypes are less severe than those conferred by knockdown of ccm1, 
ccm2, or heg, but qualitatively similar.  Second, mild knockdown of ccm2l enhances the dilated 
heart phenotype in embryos treated with a subphenotypic dose of ccm1 morpholino.  This 
morpholino co-injection technique was previously used to link heg to the CCM pathway (Mably 
et al., 2006), and that finding was subsequently validated by genetic and biochemical 88 
 
experiments in mouse (Kleaveland et al., 2009).  Third, ccm2l knockdown phenotypes can be 
partially rescued by overexpression of ccm2, suggesting that the two genes have partially 
overlapping in vivo functions.  Fourth, Ccm2l protein can bind Ccm1. 
We propose a model in which Ccm2 and Ccm2l function similarly in the Heg-CCM 
complex (Figure 3.6).  Both Ccm2 and Ccm2l bind the N-terminal region of Ccm1 through 
Ccm1’s NPXY/F motifs, and we speculate that there is overlap between the downstream 
signaling events triggered by both interactions.  In our model, when ccm2l is knocked down, 
exogenously supplied ccm2 can recover the downstream signaling events that are common to the 
two complexes.  Thus, overexpression of ccm2 can rescue ccm2l morphant defects in a 
significant proportion of embryos.  Our rescue data are also consistent with models in which 
ccm2 functions downstream of ccm2l, but we favor the interpretation that they have 
interchangeable in vivo functions because of their structural similarity and our finding that 
Ccm2l, like Ccm2, binds Ccm1. 
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Figure 3.9.  Model for the function of ccm2l in cardiovascular development.  In our model, 
Ccm2l binds Ccm1 through Ccm1’s N-terminal region. When the two NPXY motifs in Ccm1 are 
disrupted, the NPYF motif is sufficient to allow binding between Ccm1 and Ccm2l.  This differs 
from the Ccm2-Ccm1 interaction, for which the NPXY motifs are required for full-strength 
binding.  We hypothesize that although the NPXY/F motif requirements for the Ccm1-Ccm2l 
and Ccm1-Ccm2 interactions differ, the two complexes transduce partially overlapping signals. 
Thus, when Ccm2l levels are reduced, exogenously supplied Ccm2 can rescue heart morphology 
and blood circulation in a substantial proportion of embryos.  The downstream signaling events 
common to the Ccm1-Ccm2 and Ccm1-Ccm2l interactions are essential for normal 
cardiovascular development, and in their absence the endocardium and inflow tract become 
dilated and blood circulation is compromised. 
 
  The molecular details of how Ccm2l interacts with other proteins in the Heg-CCM 
pathway are unknown.  For example, it is unclear whether Ccm1 binds to Ccm2 and Ccm2l in a 
mutually exclusive manner in vivo, or whether Ccm2 and Ccm2l can simultaneously bind Ccm1.  
It is interesting to note here that the first two NPXY/F motifs in Ccm1 are jointly necessary for 
binding to Ccm2 but dispensable for binding to Ccm2l, which raises the possibility that Ccm2 90 
 
and Ccm2l bind different NPXY/F motifs in vivo and might be able to bind Ccm1 
simultaneously.  Finer mutational analysis of the NPXY/F motifs in Ccm1 and biochemical 
characterization of in vivo Heg-CCM complexes will be required to resolve this question.  
Additionally, more analysis will be required to determine whether the third NPXY/F motif in 
Ccm1 is the site of Ccm2l binding, or whether due to redundancy, any NPXY/F motif by itself 
would be sufficient for binding to Ccm2l. 
The third NPXY/F motif, the only one of the three motifs with a phenylalanine (F) 
instead of a tyrosine (Y) in the fourth position, is also interesting for another reason.  In general, 
NPXY and NPXF motifs bind similar targets but only NPXY motifs can be regulated by tyrosine 
phosphorylation.  However, in Ccm1, the third position in the NPXF motif is occupied by a 
conserved tyrosine, and a recent mass spectrometry study found that this residue was the only 
detectable phosphotyrosine in human CCM1 (Kim et al., 2011).  In future studies it will be 
valuable to determine whether phosphorylation at this site regulates binding of Ccm1 to Ccm2 
and/or Ccm2l. 
   
ccm2l in zebrafish and in mouse 
While this paper was under review, our colleagues published a study of the function of 
the mouse ortholog of ccm2l (Zheng et al., 2012).  Some of the findings of Zheng et al. on the 
role of Ccm2L in mouse are consistent with our findings on the role of ccm2l in zebrafish, and 
some are different.  Zheng et al. generate a Ccm2L knockout mouse and find that it is viable with 
no gross cardiovascular defects, unlike ccm2l morpholino-injected zebrafish embryos that exhibit 
cardiac dilation.  However, in a Ccm2L
-/- background, the Heg1
-/- phenotype is enhanced; Heg1
-/-
;Ccm2L
+/- mice can survive to birth, while Heg1
-/-;Ccm2L
-/- animals die in utero from cardiac 91 
 
defects.  This elegant genetic experiment is analogous to our morpholino co-injection 
experiments, in which we find that slight knockdown of ccm2l can enhance the cardiac defects in 
embryos sensitized with a low dose of ccm1 morpholino.  Thus, in both zebrafish and mouse, 
knockdown of Ccm2L enhances heart defects in embryos that already have a hit to the Heg-CCM 
pathway.  Interestingly, in mouse, this enhancement can be suppressed by loss of one allele of 
Ccm2.  That is, Heg1
-/-;Ccm2L
-/-;Ccm2
+/+ mice invariably die in utero, but a significant 
proportion of Heg1
-/-;Ccm2L
-/-;Ccm2
+/- mice survive until birth.  These genetic data arguing for 
antagonistic functions for Ccm2 and Ccm2L contrast with our zebrafish data showing rescue of 
ccm2l knockdown phenotypes by overexpression of ccm2. 
  We hypothesize that the difference in the relationships between ccm2 and ccm2l in 
zebrafish and mouse is due to the disparate mechanisms of heart growth that operate in the two 
species.  Zheng et al. show that Heg1
-/-;Ccm2L
-/- hearts have a reduction in both trabeculation 
and expression of growth factors known to be secreted by the endocardium to promote 
myocardial proliferation.  As a result, embryos die from inadequate heart growth, a phenotype 
that can be rescued by loss of one Ccm2 allele.  In zebrafish, however, neither trabeculation nor 
myocardial proliferation are prominent features of development during the stages of 
embryogenesis we examine.  Trabeculation in the zebrafish ventricle does not begin until 72 hpf 
(Liu et al., 2010), a time point outside of the scope of our experiments.  Although the number of 
cardiomyocytes increases between 24 and 48 hpf, proliferating cardiomyocytes are scarce; 
instead, the main mechanism of heart growth is the addition of newly differentiated 
cardiomyocytes (de Pater et al., 2009).  Given the absence of trabeculation and significant 
myocardial proliferation, we believe the control of heart development by competitive interactions 
between Ccm2 and Ccm2L observed by Zheng et al. in mouse would likely not be conserved in 92 
 
the early zebrafish embryo.  It is also possible that some of the apparently species-specific 
differences are due to different methods of gene knockdown. In the future, it will be extremely 
valuable to analyze the function of ccm2l using a zebrafish null mutant. 
 
The zebrafish heart as a model for CCM disease 
In humans, loss-of-function mutations in CCM1 and CCM2 cause vascular malformations 
of the nervous system called CCMs. CCMs share certain features with ccm1 and ccm2 mutant 
zebrafish hearts.  In both cases, vessels become severely dilated and electron microscopy reveals 
defects in the formation of tight junctions between endothelial cells (Kleaveland et al., 2009; 
Wong et al., 2000).  Owing to the genetic and cell biological similarities between the dilated 
heart phenotype in zebrafish embryos and human CCMs, we propose that the zebrafish heart has 
promise as a model to understand CCM disease.  In one human genetics study, 94% and 57% of 
patients with familial and sporadic CCM disease, respectively, had mutations in the coding 
regions of the three known CCM-associated genes (Denier et al., 2006).  Thus, there are likely 
more malformation-causing genes to be found.  Moreover, CCMs range from asymptomatic to 
fatal, so even in patients with known disease-causing mutations there may be other genetic 
modifiers that influence disease severity.  It stands to reason that genes that modify the ccm1 and 
ccm2 loss-of-function heart phenotypes in zebrafish may also influence CCM pathogenesis in 
humans.  In our studies, we identify ccm2l as an enhancer of the dilated heart phenotype in the 
zebrafish embryo.  We propose that the human homolog of ccm2l, C20ORF160, is an intriguing 
candidate gene to be investigated for mutations in patients with CCM disease of unknown 
genetic etiology or in patients with characterized mutations but unusually severe disease 
progression. 93 
 
 
Conclusions 
  We conclude that ccm2l is essential for cardiovascular development in zebrafish due to 
its function in the Heg-CCM pathway.  When ccm2l is knocked down, the embryonic atrium and 
inflow tract become dilated and blood flow is compromised.  Slight perturbation of ccm2l 
enhances the dilated heart phenotype in embryos sensitized by morpholino against ccm1, 
defining ccm2l as an enhancer of the Heg-CCM pathway.  Overexpression of ccm2 partially 
rescues ccm2l morphant defects, which suggests that ccm2 and ccm2l have overlapping in vivo 
functions. ccm2l and ccm1 are both expressed in the heart, and Ccm2l protein binds Ccm1 in an 
interaction that requires Ccm1’s NPXY/F motifs; however, unlike Ccm2, Ccm2l can bind Ccm1 
even when the first two of the three NPXY/F motifs are mutated.  Based on the role of ccm2l in 
the Heg-CCM pathway in zebrafish, the human ortholog of ccm2l, C20ORF160, may be relevant 
to human CCM disease. 
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Chapter 4: Heg-CCM and ERK signaling 
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Introduction 
 
  In all animals, signaling pathways control crucial cell functions.  One important family of 
signaling pathways is the mitogen-activated protein kinase (MAPK) pathways, which transmit 
information about the extracellular environment to the cell’s nucleus through ordered kinase 
cascades.  Like the other MAPK pathways, the extracellular signal-regulated kinase (ERK) 
pathway is an ancient, highly conserved signaling system that is crucial to normal embryonic 
development and adult physiology. 
The structure of the ERK pathway has been studied extensively (Figure 4.1).  Activation 
of the ERK pathway frequently begins with binding of a growth factor to its receptor on the 
plasma membrane.  Through intermediate scaffold proteins, activation of the receptor results in 
the conversion of GDP-bound Ras, the inactive form of the small GTPase, into Ras-GTP.  Ras-
GTP activates the kinase Raf, which in turn activates the kinases MEK1 and MEK2 by 
phosphorylation.  Finally, MEK1 and MEK 2 activate the two ERK paralogs, ERK1 and ERK2.  
ERK1 and ERK2, themselves kinases, phosphorylate a dizzying array of cytoplasmic and nuclear 
substrates, including kinases, cytoskeletal components, and transcription factors (Roskoski, 
2012).  101 
 
 
Figure 4.1.  The ERK pathway.  This diagram represents a simplified version of the ERK 
pathway and indicates where CI-1040 and the MEK1DD protein inhibit and activate the 
pathway, respectively.  MEK1DD is constitutatively active because, unlike endogenous MEK1, 
it is not subject to regulation by the pathway’s upstream components. 
 
Properly regulated Erk signaling is required for normal heart development in zebrafish.  
Embryos injected with morpholinos targeting either erk1 or erk2 exhibit, amongst other severe 
defects, pericardial edema and possibly enlarged heart chambers (Krens et al., 2008).  Similarly, 
sustained treatment with the MEK1/2 inhibitor PD0325901 causes pericardial edema and a 
blockage of circulation in many embryos (Anastasaki et al., 2012).  When the upstream activator 
raf1 is knocked down by morpholino injection, affected embryos exhibit enlarged atria 
(Razzaque et al., 2007).  Conversely, when Erk is hyperactivated by global expression of a 
constitutatively active mek1 construct, a proportion of embryos exhibit small, dysfunctional 
hearts (Bolcome and Chan, 2010). 
Since Cerebral cavernous malformation 2 (Ccm2) was originally discovered as a 
necessary component of the p38 MAPK complex (Uhlik et al., 2003), much research has been 102 
 
devoted to understanding the functions of Heart of glass-Cerebral Cavernous Malformation 
(Heg-CCM) pathway members in regulating MAPK pathways.  It has been shown that CCM1 
negatively regulates ERK in human umbilical vein endothelial cells (HUVECs).  Moreover, ERK 
is hyperactivated in resected CCM lesions, and in a model of CCM disease involving 
transplantation of CCM1-depleted HUVECs into mice, chemical inhibition of ERK ameliorated 
the HUVECs’ CCM-like phenotype (Wustehube et al., 2010).  Thus, there is evidence that Ccm1 
negatively regulates ERK in the context of CCM disease; however, the nature of the relationship 
between the Heg-CCM pathway and ERK in heart development is unknown. 
In this chapter, we investigate the relationship between HEG1 and ERK in HUVECs and 
in the developing zebrafish heart.  We find that Heg and Erk interact differently in these two 
biological contexts.  We show that Erk hyperactivation can partially rescue heg morphant 
cardiovascular defects and propose a model whereby endocardial Heg positively regulates 
myocardial Erk. 
    
Materials and methods 
 
Zebrafish experiments 
Tubingen (wildtype) and hsp70:mek1DD zebrafish were used (Bolcome and Chan, 
2010).  Embryos from the former were maintained at 28.5 °C, while embryos from the latter 
were maintained at 26 °C to avoid undesired heat shock.  cmlc2:mek1DD fish were generated by 
performing tol2 cloning with the mek1DD middle entry vector (Bolcome and Chan, 2010) and a 
5’ entry vector we previously generated containing the cmlc2  promoter (Sogah et al., 2010). 103 
 
Injections were performed as previously described (Rosen et al., 2009) using a previously 
validated morpholino against heg (Mably et al., 2003).  Embryos were treated with 1.5 µM CI-
1040 (Axon Medchem) in dimethyl sulfoxide (DMSO) or an equivalent amount of vehicle 
starting at 24 hpf.  Heat shock was performed for 2-3 hours early on the second day of 
development. 
 
Cell culture and western blotting 
  HUVECs were maintained and transfected and western blots were performed as 
described in chapter 2 of this dissertation.  Phosphorylated ERK and total ERK antibodies were 
used on western blots as per the manufacturer’s instructions (Cell Signaling Technology).  
GAPDH and Heg antibodies were used as described in Chapter 2 of this dissertation.  
Quantitative densitometry analysis of western blots was performed using ImageJ software. 
 
Microscopy 
  Images of live zebrafish embryos were captured and processed as described in Chapter 2. 
 
Results 
 
  Because depletion of CCM1 protein in HUVECs has been shown to cause an increase in 
ERK activation (Wustehube et al., 2010), we were interested to determine whether HEG1, which 
binds CCM1, also works to suppress ERK activity.  We found that siRNA-mediated knockdown 
of HEG1 protein in HUVECs causes an increase in both phosphorylated ERK and total ERK 
protein when cells are starved and then stimulated with full media (Figure 4.2A).  Densitometry 104 
 
analysis of western blot bands revealed that although the proportion of ERK that is 
phosphorylated is not affected by HEG1 knockdown, the ratio of phosphorylated ERK to 
GAPDH is increased (Figure 4.2B).  Thus, HEG1 seems to restrict the abundance of activated 
ERK protein not by regulating the phosphorylation of ERK, but by controlling the levels of total 
ERK. 
 
 
Figure 4.2.  Heg knockdown increases p-ERK levels in HUVECs.  (A) Knocking down HEG1 
in HUVECs with two different siRNAs causes an increase in phosphorylated ERK (p-ERK) and 
total ERK, relative to cells transfected with negative control siRNA.  (B) Densitometry analysis 
was performed on bands from western blot experiments comparing protein levels in HUVECs 
transfected with anti-HEG1 siRNA 33148 and HUVECs transfected with negative control 
siRNA.  The p-ERK/total ERK ratio is unaffected by depletion of HEG1, but the p-
ERK/GAPDH ratio is more than 1.5 fold higher in cells lacking HEG1.  Error bars represent 
standard error from three independent experiments. 
 
  Since HEG1 negatively regulates ERK in HUVECs, we hypothesized that Heg opposes 
Erk in zebrafish heart development as well.  According to our hypothesis, inhibition of Erk 
signaling ought to decrease the size of the heart, as opposed to Heg knockdown, which increases 
the size of the heart.  Interestingly, we observed the opposite result.  We incubated embryos in 105 
 
CI-1040, a highly specific small molecule that inhibits Mek1 and Mek2, the two kinases that 
activate Erk.  We frequently observed increases in the size of the atrium, reminiscent of heg 
mutant embryos (Figure 4.3A,B).  Consistent with this result, it has been shown by others that 
global activation of Erk due to organism-wide induction of a phosphomimetic mek1 gene, which 
produces a constitutatively active Mek1 protein (Mek1DD) that hyperactivates Erk, confers a 
severe reduction in the size of the heart (Bolcome and Chan, 2010).  Thus, like Heg, Erk activity 
appears to restrict the size of the heart.   Moreover, we generated transgenic fish in which Erk is 
hyperactivated just in the myocardium by tissue-specific expression of the same transgene and 
found that this is sufficient to cause an extreme reduction in heart size (Figure 4.3C). 
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Figure 4.3.  Global Erk activation rescues circulation in heg morphants.  (A-C) Chemical 
inhibition of the Erk pathway causes an increase in the size of the atrium, while genetic 
hyperactivation of the Erk pathway causes a decrease in the size of the atrium.  (D) Following 
heg knockdown, transgenic activation of Erk signaling restores circulation in a statistically 
significant proportion of embryos. The p-value was calculated from a 2x2 contingency table 
using Fisher’s exact test.  (E) Examples of embryos from the rescue experiments.  Both embryos 
pictures were injected with heg morpholino and heat shocked; the embryo on the left was 
genetically wildtype and exhibited a severe heart phenotype including a lack of circulation, while 
the embryo on the right expressed the transgene, had heart morphology that was closer to 
normal, and had robust circulation of red blood cells. 
 
Since we found that Erk and Heg regulate heart morphology in similar fashions, we 
sought to test the hypothesis that Erk is a downstream effector of Heg.  For this experiment, we 
used the hsp70:mek1DD fish line, in which heat shock induction leads to global expression of 
Mek1DD and Erk hyperactivation (Bolcome and Chan, 2010).  We crossed hsp70:mek1DD fish 
with wildtype fish to create clutches containing comparable numbers of transgenic and wildtype 107 
 
embryos.  We injected embryos with heg morpholino and heat shocked them early on the second 
day of development.  At 48 hpf, we separated transgenic embryos from their wildtype siblings on 
the basis of whether they express the transgene’s GFP reporter, and scored for circulation down 
the trunk of the embryo.  We used circulation for our assay rather than heart morphology to 
distinguish whether expression of the transgene merely shrinks the big heart or actually restores 
cardiovascular function in heg morphants.  We found that after heat shock, a higher proportion of 
transgenic embryos than wildtype embryos had circulation (Figure 4.3D).  The difference 
between groups is modest in the sense that regardless of genotype, the majority of embryos lack 
circulation.  However, the difference is statistically highly significant.  Thus, hyperactivation of 
Erk partially rescues heg morphant cardiovascular defects. 
 
Discussion 
 
The relationships between Heg and Erk in HUVECs and in the zebrafish heart 
  In this chapter, we investigate the relationship between Heg and ERK signaling in 
primary endothelial cells and the zebrafish heart.  We find that in HUVECs, siRNA-mediated 
depletion of HEG1 causes an increase in the levels of total ERK and phosphorylated ERK, 
suggesting an antagonistic relationship between HEG1 and ERK.  Paradoxically, Heg and Erk 
appear to regulate zebrafish heart morphology in similar ways, such that inhibition of either 
causes severe dilation, raising the possibility that the two genes function cooperatively in the 
zebrafish heart.  The notion of a cooperative interaction between the two genes is supported by 
our findings that Erk activation can rescue heg morpholino-induced circulatory block in a 
statistically significant proportion of embryos. 108 
 
To reconcile our phenotypic results suggesting that Erk functions downstream of Heg in 
heart development with our data showing that HEG1 negatively regulates ERK in HUVECs, we 
hypothesize that when we rescue heg morphant embryos by globally activating Erk, the relevant 
Erk activity is in the myocardium.  That is to say, it may be the case that in heg morphants there 
is a glut of activated Erk in the endocardium, as in HEG1-depleted HUVECs, but it is the activity 
of Erk in the myocardium that is controlling heart size.  This hypothesis is supported by our 
finding that hyperactivation of Erk solely in the myocardium is sufficient to shrink the heart. 
 
Two models to explain the rescue of heg morphant defects by Erk hyperactivation 
We propose two models to explain our rescue results (Figure 4.4).  In our first model, 
endocardial Heg positively regulates Erk activity in the myocardium, and Erk in the myocardium 
regulates heart morphology.  When Heg is lost from the endocardium, Erk activity in the 
myocardium is reduced, and the heart dilates as in embryos treated with the Mek1/2 inhibitor CI-
1040.  It is possible that endocardial Heg, being a transmembrane protein, could directly contact 
the myocardium to regulate the Erk pathway at a time point before the two heart tissues are 
separated by extracellular matrix.  Alternatively, there could be a secreted endocardial factor 
downstream of Heg that activates Erk in the myocardium.  This model is not mutually exclusive 
with models for Heg-CCM function that emphasize the role of that pathway in regulating 
endothelial junctions and vessel structure.  It may be the case that the heg
-/- heart is so big 
because Heg constrains heart size by multiple mechanisms, all of which are lost in the mutant. 
 109 
 
 
Figure 4.4.  Models to explain the rescue of heg morphants by Erk activation.  These 
schematics illustrate a cross-sectional view through a heart chamber, with the endocardium in 
blue and the myocardium in red.  (A) and (B) represent two different models.  (A) In a wildtype 
embryo, endocardial Heg activates Erk in the myocardium.  Myocardial Erk constrains the size 
of the heart.  When Heg is depleted by morpholino, Erk activity is lost from the myocardium, 
and the heart expands.  When Erk is added back through a transgene, the myocardial Erk lost due 
to Heg depletion is restored, and heart size is constrained as normal.  (B) In a wildtype embryo, 
Heg in the endocardium and Erk in the myocardium independently constrain the size of the heart.   
When Heg is depleted by morpholino, myocardial Erk is unaffected, but the constraining force of 
Erk is insufficient to prevent dilation of the heart.  When Erk is added by a transgene, the extra 
size-constraining activity in the myocardium can make up for the same activity lost in the 
endocardium by Heg knockdown. 
 
Our second model posits an indirect relationship between Heg and Erk in heart 
development.  In this model, the Heg-CCM pathway and Erk function independently in the 
regulation of heart size, such that Erk activity is not reduced in the heg morphant.  Even so, 
because Erk functions in the myocardium to restrict the size of the heart, experimental 
hyperactivation of Erk reverses the heg morphant phenotype. 110 
 
  To distinguish between these models, it will be crucial to determine whether Erk 
activation in the myocardium is decreased in heg mutants, either by comparing phosphorylated 
Erk or the mRNA levels of Erk transcriptional targets in wildtype and heg mutant embryos.  If 
Erk activity is indeed decreased in the myocardium of heg mutants, that would argue for our first 
model.  To confirm either of our models, it will also be necessary to demonstrate that 
myocardial-specific loss of Erk function can increase the size of the heart, as myocardial-specific 
Erk gain-of-function can shrink it.  With the exception of a study demonstrating a non-
autonomous role for Heg in regulating hepatic polarization (Sakaguchi et al., 2008), most 
research on the Heg-CCM pathway has focused on its tissue-autonomous functions; the project 
summarized in this chapter, still in its infancy, should be valuable in helping us understand Heg-
CCM pathway-mediated interactions between tissues. 
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Chapter 5: Discussion 
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In this dissertation, I describe experiments designed to elucidate the function of the Heg-
CCM pathway.  Chapters 2 through 4 each contain a Discussion section that summarizes and 
discusses our findings.  This chapter begins by highlighting findings of particular interest for 
further discussion, with an emphasis on future directions, and ends with a comparison between 
the Heart of glass-Cerebral Cavernous Malformation (Heg-CCM) pathway in zebrafish and 
mammals and a discussion of the utility of the zebrafish heart as a CCM disease model. 
 
Heg undergoes a cleavage event of unknown function 
 
  We have found that the C-terminal, intracellular domain of the transmembrane protein 
Heg is cleaved from the full-length protein.  This occurs with endogenous Heg in human 
umbilical vein endothelial cells (HUVECs) and when Heg is transfected in 293T cells.  The 
former suggests that the cleavage is authentic and not an artifact of overexpression; the latter 
suggests that the small protein product is the result of cleavage and not alternative splicing, since 
alternative splicing cannot occur in RNA transcribed from a plasmid lacking introns. 
  The function of this cleavage event is unknown and a ripe target for future research.  One 
hypothesis is that the cleaved fragment has activity distinct from the full-length protein, and that 
the cleavage of Heg is a regulated event necessary for certain outputs of the Heg-CCM pathway.  
One way this could occur would be if cleaved Heg were released from the plasma membrane and 
allowed to interact with previously inaccessible targets in the cytoplasm.  The intracellular 
domain of Heg (HegICD) has a NPXF motif, and NPXF motifs are known to interact with PTB 
domains.  The FERM domain of Ccm1, Heg’s only known interactor, contains a PTB 
subdomain; surprisingly, however, the NPXF motif in HegICD is not required for the HEG1-114 
 
CCM1 interaction (Gingras et al., 2012).  Perhaps HegICD’s NPXF motif is involved in other, 
cytoplasmic interactions. 
  It is also possible that HegICD has activity in the nucleus.  Ccm1 has been shown to have 
functional nuclear localization sequences (NLS) (Zawistowski et al., 2005), but its nuclear 
function is unknown.  HegICD has no NLS, but it is interesting to speculate that Ccm1 could 
transport it across the nuclear membrane.  Although HegICD does not have DNA binding 
domains, one can imagine it affecting gene expression by forming complexes with transcription 
factors or other DNA or chromatin regulators.  The extensively studied Notch protein may serve 
as a useful analogy to understand Heg function.  Heg and Notch are both single-pass 
transmembrane proteins with extracellular domains that are subject to glycosylation and contain 
EGF-like repeats.  After Notch interacts with its transmembrane ligand, sequential cleavage 
events result in the release of the Notch intracellular domain (NICD) from the plasma membrane.  
NICD then translocates to the nucleus, where it complexes with CBF1–SU(H)–LAG1 (CSL) and 
the transcriptional co-activator Mastermind-like (Mml) to activate target genes (Guruharsha et 
al., 2012). 
In the future, it will be interesting to determine whether HegICD behaves similarly to 
NICD.  One useful approach will be to perform immunofluorescent antibody staining for 
endogenous HegICD to chart its localization under different conditions.  If cleavage requires 
binding of a particular ligand to the extracellular domain of Heg, then isolation of this ligand 
might be a challenging but necessary task.  It will also be informative to perform Edman 
Degradation to determine the exact site of cleavage, which might yield clues as to the regulation 
of that event. 115 
 
Alternatively, the cleavage of Heg might be a regulatory mechanism to decrease Heg-
CCM signaling.  Heg is thought to anchor Ccm1 to endothelial cell junctions (Gingras et al., 
2012), where it suppresses RhoA activity (Borikova et al., 2010; Stockton et al., 2010) and 
inhibits the expression of Wnt target genes by preventing the internalization of β-Catenin 
(Glading and Ginsberg, 2010).  Cleavage of HegICD might lead to the release of Ccm1 from the 
junction, relieving to some degree the inhibition of the RhoA and Wnt pathways.  Since cleavage 
of Heg is presumably a more rapid event than transcriptional regulation, this strategy would 
allow the cell to quickly respond to situations requiring the downregulation of Heg-CCM 
signaling. 
 
ccm2l  
 
  We found that the novel, conserved gene ccm2l is required for normal heart development 
in the zebrafish embryo.  When we knock down ccm2l with two different morpholinos targeted 
to exon-intron junctions, we observe dilation of the heart and inflow tract, and in extreme cases, 
a complete cessation of blood circulation.  Slight knockdown of ccm2l can enhanced the dilated 
heart phenotype in embryos sensitized with a low dose of ccm1 morpholino, overexpression of 
ccm2 can partially rescue ccm2l morphant defects, and Ccm2l protein can bind Ccm1. 
  Our results led us to propose a model in which ccm2 and ccm2l have partially 
overlapping functions in heart development.  In our model, Heg-CCM protein complexes can 
contain either Ccm2 or Ccm2l, and these two different complexes have partially overlapping 
downstream signaling targets.  We believe that in our rescue experiments, overexpressed ccm2 
leads to an increased number of Heg-Ccm1-Ccm2 complexes that can reach the targets normally 116 
 
acted upon by the Heg-Ccm1-Ccm2l complex.  This leads to rescue of cardiovascular 
development. 
  Although ccm2 and ccm2l have partially overlapping functions in heart development, 
they do not function redundantly, as knockdown of either individually is sufficient to confer a 
heart phenotype.  This suggests that, although exogenous ccm2 can rescue ccm2l morphant 
defects, the embryo does not have a mechanism to increase expression of ccm2 in response to 
loss of ccm2l.  (Alternatively, the embryo may upregulate ccm2 expression at a level insufficient 
to induce rescue in all embryos; measurement of transcript levels by quantitative RT-PCR would 
be required to determine this.)  We also emphasize that our phenotypic data indicate that the 
functions of ccm2 and ccm2l are partially overlapping but not identical, since ccm2 mRNA 
injection rescues nearly 100% of vtn mutants (Mably et al., 2006) but only approximately 50% of 
affected ccm2l morphants. 
  Why is the ccm2 loss-of-function phenotype more severe than that for ccm2l?  One 
possibility is that the ccm2l phenotype is relatively mild because knockdown is incomplete.  
Another possibility is that the protein complexes containing Ccm2 generate the bulk of the 
downstream Heg-CCM signals, either because that complex has greater activity or because 
Ccm2 is present at a higher level in the cell than Ccm2l.  Thus, loss of ccm2 would have a more 
profound effect on the embryo than loss of ccm2l. 
  The downstream targets of Ccm2 and Ccm2l in heart development are unknown, and 
their identification should provide a wealth of knowledge about how the Heg-CCM pathway 
regulates cardiac morphology.  According to our model, some of these targets would be shared 
by Ccm2 and Ccm2l, and others would be unique to one or the other.  In the last several years, 
multiple pathways have been shown to be affected by loss of ccm2, both in cell culture and in the 117 
 
adult mouse vasculature.  These pathways, which include RhoA/ROCK (Crose et al., 2009; 
Stockton et al., 2010; Whitehead et al., 2009) , Wnt/ β-catenin signaling (Glading and Ginsberg, 
2010), and the p38 stress response (Uhlik et al., 2003), represent a rich pool of candidates to be 
tested as downstream effectors of Ccm2 and Ccm2l in heart development. 
 
Heg and Erk regulate heart development 
 
  It has previously been shown in HUVECs that depletion of CCM1 leads to 
hyperactivation of ERK and that overexpression of CCM1 leads to a reduction in ERK activation 
(Wustehube et al., 2010).  We used siRNAs to deplete HEG1 from HUVECs and found that this 
causes an increase in the amount of activated ERK.  Since loss of heg and ccm1 in zebrafish 
affect heart development in the same way, it is not surprising that HEG1, like CCM1, negatively 
regulates ERK in HUVECs. 
  What is surprising, however, is that the relationship between Heg and Erk in heart 
development appears to be quite different from their relationship in HUVECs.  Chemical 
inhibition of Mek1/2, the kinases that activate Erk, results in a dilated heart phenotype 
reminiscent of the heg mutant, suggesting that Heg does not negatively regulate Erk in the heart.  
Moreover, global activation of Erk in transgenic embryos rescues circulation in a statistically 
significant proportion of embryos injected with morpholino against heg.  This finding raises the 
possibility that Heg positively regulates Erk in vivo. 
  Our zebrafish data suggesting that Heg positively regulates Erk and our HUVEC data 
showing a negative interaction can be reconciled by models emphasizing signaling between the 
two tissues of the zebrafish heart.  We hypothesize that endocardial Heg may negatively regulate 118 
 
endocardial Erk, recapitulating the interaction we observed in HUVECs.  However, in our 
model, endocardial Heg positively regulates Erk in the myocardium, and it is myocardial Erk 
rather than endocardial Erk that regulates heart morphogenesis.  A crucial function for 
myocardial Erk in heart development is suggested by our finding that hyperactivation of Erk 
specifically in the myocardium results in a shrunken heart. 
  In the future, several key experiments will have to be done to validate this model.  First, it 
will need to be shown that Erk signaling is decreased in the myocardium of heg mutants.  This 
can be done either with a phospho-specific Erk antibody or by measuring mRNA levels of Erk 
transcriptional targets.  Second, this model requires that myocardial-specific loss of Erk activity 
be sufficient to cause severe heart dilation.  This can be determined by generating zebrafish 
expressing a dominant negative mek1 transgene specifically in the myocardium.  Third, our 
rescue experiments ought to be repeated with myocardial-specific activation of Erk.  This 
presents a challenge, as we have shown that this condition causes a dramatic shrinkage of the 
heart, a phenotype that would probably preclude embryos from exhibiting rescue of the heg 
phenotype.  A possible solution to this problem would be to generate transgenic zebrafish 
employing the Tet-On system, in which temporal specificity can be achieved by administration 
of doxycycline.  Perhaps by activating Erk in the myocardium relatively late in development, we 
could avoid the extreme defects we see in cmlc2:mek1DD embryos.  The Tet-On system has 
been used successfully to temporally regulate expression of transgenes in the myocardium 
(Huang et al., 2005). 
  An alternative model to explain the rescue of heg morphant embryos by global Erk 
activation is that Heg and Erk regulate heart size similarly but independently.  In other words, 
Heg and Erk both restrain the size of the heart, but neither affects the function of the other.  If we 119 
 
found that heg mutants exhibit normal levels of phospho-Erk and transcription of Erk-regulated 
genes, that would be evidence for this model.  To distinguish between the two models, it will 
also be informative to perform cell counts on embryos treated with the MEK1/2 inhibitor CI-
1040.  An interesting feature of the heg mutant is that, although the heart is enormous, the 
number of cardiomyocytes is the same as in wildtype embryos.  If this is the case for CI-1040 
treated embryos, that would be consistent with the notion of Erk and Heg operating by a 
common mechanism.  If CI-1040 treated embryos have more cardiomyocytes that normal, that 
would argue for inhibition of Erk and Heg causing an enlarged heart by independent 
mechanisms. 
 
The Heg-CCM pathway in zebrafish and mammals 
 
In this dissertation we use the zebrafish to analyze various aspects of the Heg-CCM 
pathway, with a mind toward applying our findings to the understanding of human CCM disease.  
In this final section, I compare our work in zebrafish to analogous studies in mouse and human 
and finish by describing the strengths and limitations of the zebrafish heart as a model for 
understanding CCM disease. 
  We performed a yeast 2-hybrid screen using the intracellular domain of zebrafish Heg as 
bait, and we recovered a large number of clones encoding fragments of Ccm1.  We subsequently 
validated the Heg-Ccm1 interaction through co-immunoprecipitation of proteins generated by in 
vitro translation and in the 293T cell overexpression system.  While our work was in progress, it 
was published by others that the mouse orthologs of Heg and Ccm1 bind as well (Kleaveland et 
al., 2009).  Thus, the Heg-Ccm1 interaction is conserved between zebrafish and mammals.  Our 120 
 
finding that this interaction is mediated by the FERM domain of Ccm1 was validated in 
mammals as well (Gingras et al., 2012). 
In zebrafish, the physical interaction between Heg and Ccm1 was predicted by the 
finding that the heg and san mutants have nearly identical phenotypes (Mably et al., 2006).  In 
mouse, interestingly, the Ccm1 and Heg1 knockouts have quite different phenotypes; Ccm1 
knockouts die in utero from severe vascular defects (Whitehead et al., 2004), while Heg1 
knockouts usually die postnatally from cardiac or pulmonary rupture (Kleaveland et al., 2009).  
The discrepancy between the Ccm1 and Heg1 mouse phenotypes makes it particularly 
remarkable that the biochemical interaction is conserved.  One possible explanation for why the 
mouse Heg1 knockout phenotype is relatively weak is that mammals have additional 
transmembrane proteins that offer some redundancy.  This would also explain why, to date, no 
HEG1 mutations have been identified in CCM patients. 
  A comparison of our study of ccm2l in zebrafish to the analogous study in mouse (Zheng 
et al., 2012) provides another example of Heg-CCM biochemical interactions being conserved 
between species; however, in this case, the developmental function of the same interaction seems 
to be different in mouse and zebrafish.  In both species, it was found that ccm1 and ccm2l are 
expressed in the heart and their protein products can physically interact.  However, in zebrafish, 
the gain of ccm2 rescues heart defects in ccm2l morphants, whereas in mouse, the loss of ccm2 
rescues heart defects in Ccm2l
-/-;Heg1
-/- animals.  As we explain in the discussion section of 
Chapter 3 of this dissertation, we hypothesize that this difference in the relationship between 
ccm2 and ccm2l relates to the different modes of heart development in zebrafish and mouse.  In 
the mouse embryo, heart growth is accomplished primarily by myocardial proliferation, a 
process promoted by ccm2l.  However, in early zebrafish embryos, heart growth is mainly 121 
 
accomplished by differentiation of new cardiomyocytes, not proliferation of existing ones (de 
Pater et al., 2009).  Thus, we hypothesize, an antagonistic relationship between ccm2 and ccm2l 
in regulation of heart growth would not be conserved in the early zebrafish embryo, even though 
Ccm2l may interact with the same proteins in both systems. 
  A third interaction we studied—between Heg and Erk—is quite different in human 
CCMs and the zebrafish heart.  We have found that global inhibition of Erk with the Mek1/2 
inhibitor CI-1040 results in a dilated heart, myocardial-specific activation of Erk results in a 
shrunken heart, and, most interestingly, global activation of Erk can rescue heg morphant heart 
defects.  Given the histological and cell biological similarities between heg mutant hearts and 
CCM lesions, this finding raises the possibility that pharmaceuticals that activate ERK might be 
useful in treating CCMs in human patients.  A limited number of small molecules that activate 
ERK are available and have shown promise in animal models of a different disease (Maher et al., 
2011). 
  And yet, despite the similarities between the two systems, treatment of CCM disease with 
ERK activators would be unwise.  Unlike the endothelium in heg and san mutants, CCM lesion 
endothelium is hyperproliferative, a phenotype thought to contribute to the disease.  ERK is 
known to stimulate proliferation generally, and it has been shown that resected CCM lesions 
have increased ERK activation.  Furthermore, in a CCM model in which HUVECs depleted of 
CCM1are grafted into mice and form vessels with features of CCM pathology, treatment with 
the ERK pathway inhibitor Sorafenib (which inhibits other kinases as well) can ameliorate 
CCM-like phenotypes (Wustehube et al., 2010).  It stands to reason that drugs that activate ERK 
could worsen outcomes in CCM patients. 122 
 
  Why are Heg-CCM loss-of-function phenotypes rescued by Erk activation in the 
zebrafish heart but by ERK inhibition in a mouse CCM model?  Here, the discrepancy is 
probably not due to species-specific roles for Heg-CCM genes and ERK, but rather to organ-
specific roles for Heg-CCM genes and ERK.  Erk activation likely rescues circulation in heg 
morphants due to its effects in the myocardium, a tissue that is probably irrelevant to human 
CCM disease.  And Sorafenib rescues CCM-like pathology in the mouse model by suppressing 
endothelial hyperproliferation, a defect absent from the mutant zebrafish heart’s endocardium. 
  All that considered, does the embryonic zebrafish heart have value as a model for CCM 
disease?  The answer is probably yes—but with certain limitations.  Human CCM lesions are 
dilated, have reduced cell junctions, and are hyperproliferative.  The zebrafish Heg-CCM 
mutants have the first two phenotypes but not the third; thus, for chemical or genetic 
interventions targeting vessel dilation and cell junctions, the zebrafish heart may faithfully 
recapitulate the human disease, while interventions that could improve patient outcomes by 
reducing endothelial proliferation might have no effect on the zebrafish heart.  The second 
challenge is posed by the myocardium.  It is easy to envision large scale screens designed to 
identify small molecules that can rescue heg, san, or vtn heart defects as a proxy for CCM 
lesions.  Any hits from such a screen would have to be evaluated in a tissue-specific fashion, as 
there is no reason to expect that treatments that work primarily by affecting the myocardium 
would have a beneficial role in the brain vasculature.  However, a molecule that rescued the 
mutant heart by primarily affecting the endocardium might be an interesting candidate as a 
therapeutic for CCM disease. 
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Appendix: List of hits from yeast 2-hybrid screen, in order of sequencing plate position. 
  
 
 
 
 
 
 
 
 
Sequence ID  Contig #  Danio EntrezGene name 
Human EntrezGene 
name 
# 
reads 
plate01A01.b  singlet 
 
MAT2B  1 
plate01A02.b  singlet   ENSDARG00000078882  -  1 
plate01A03.b  49 
 
RNF2  10 
plate01A04.b  singlet 
 
ACACA  1 
plate01A05.b  45 
 
COL1A2  6 
plate01A06.b  50 
 
TTN  10 
plate01A07.b  31 
 
SMARCB1   3 
plate01A08.b  50 
 
TTN  10 
plate01A09.b  49 
 
RNF2  10 
plate01A10.b  singlet 
 
TRIP11  1 
plate01A11.b  40 
 
FLNA  4 
plate01A12.b  singlet 
 
NCLN  1 
plate01B01.b  singlet 
 
KDM6A  1 
plate01B02.b  singlet  -  -  1 
plate01B03.b  40 
 
FLNA  4 
plate01B04.b  51 
 
TTN  11 
plate01B05.b  41 
 
PIH1D1  4 
plate01B06.b  2 
 
CPT1A   1 
plate01B07.b  32 
 
GRB10   3 
plate01B08.b  31 
 
SMARCB1   3 
plate01B09.b  singlet  LOC567179, LOC557901 (weak)  -  1 
plate01B10.b  42 
 
CCDC80  4 
plate01B11.b  46 
 
DHRS4  6 
plate01B12.b  singlet 
 
ELF2  1 
plate01C01.b  13 
 
SMOX  2 
plate01C02.b  singlet 
 
RPS27A  1 
plate01C03.b  50 
 
TTN  10 
plate01C04.b  singlet 
 
FBP2  1 
plate01C05.b  14 
 
SART3   2 
plate01C06.b  15 
 
HMCN1   2 
plate01C07.b  43 
 
COL1A2  4 
plate01C08.b  singlet 
 
GCAT  1 126 
 
plate01C09.b  46 
 
DHRS4  6 
plate01C10.b  16 
 
C5orf44   2 
plate01C11.b  17 
 
RNF2  2 
plate01C12.b  17 
 
RNF2  2 
plate01D01.b  51 
 
TTN  11 
plate01D02.b  singlet 
 
MDH1  1 
plate01D03.b  43 
 
COL1A2  4 
plate01D04.b  33 
 
CCDC80  3 
plate01D05.b  47 
 
KRIT1  6 
plate01D06.b  47 
 
KRIT1  6 
plate01D07.b  singlet 
 
CDK1  1 
plate01D08.b  singlet 
 
GFM2  1 
plate01D09.b  40 
 
FLNA  4 
plate01D10.b  singlet 
 
-  1 
plate01D11.b  18  hbs1l (with intron?)  HBS1L  2 
plate01D12.b  31 
 
SMARCB1   3 
plate01E01.b  19 
 
TTN  2 
plate01E02.b  singlet 
 
PLOD1  1 
plate01E03.b  38 
 
LOX  3 
plate01E04.b  singlet  -  -  1 
plate01E05.b  singlet 
 
TUBGCP4  1 
plate01E06.b  14 
 
SART3   2 
plate01E07.b  singlet 
 
HSPB1  1 
plate01E08.b  51 
 
TTN  11 
plate01E09.b  20 
 
MYBPC3  2 
plate01E10.b  45 
 
COL1A2  6 
plate01E11.b  50 
 
TTN  10 
plate01E12.b  21 
 
FLNC  2 
plate01F01.b  singlet 
 
ABI3BP  1 
plate01F02.b  3 
 
KRIT1  1 
plate01F03.b  1 
 
CILP  1 
plate01F04.b  singlet 
 
ARCN1  1 
plate01F05.b  singlet 
 
PCBP2  1 
plate01F06.b  singlet 
 
SHMT1  1 
plate01F07.b  singlet 
 
ANXA1  1 
plate01F08.b  20 
 
MYBPC3  2 
plate01F09.b  32 
 
GRB10   3 
plate01F10.b  singlet 
 
TRIM50  1 
plate01F11.b  46 
 
DHRS4  6 
plate01F12.b  singlet 
 
MANEA   1 
plate01G01.b  singlet 
 
DNAJA2   1 
plate01G02.b  51 
 
TTN  11 
plate01G03.b  singlet 
 
AUH   1 127 
 
plate01G04.b  singlet 
 
ID2  1 
plate01G05.b  47 
 
KRIT1  6 
plate01G06.b  43 
 
COL1A2  4 
plate01G07.b  singlet 
 
GNB5  1 
plate01G08.b  4 
 
SMARCB1   1 
plate01G09.b  singlet 
 
SDHA  1 
plate01G10.b  singlet 
 
SND1  1 
plate01G11.b  singlet  myst3 (in intron?)  -  1 
plate01G12.b  singlet 
 
APBA1  1 
plate01H01.b  singlet 
 
PKM2  1 
plate01H02.b  44 
 
GSR  4 
plate01H03.b  43 
 
COL1A2  4 
plate01H04.b  33 
 
CCDC80  3 
plate01H05.b  41 
 
PIH1D1  4 
plate01H06.b  49 
 
RNF2  10 
plate01H07.b  singlet 
 
CARKD  1 
plate01H08.b  34 
 
FLNA  3 
plate01H09.b  48 
 
CILP  6 
plate01H10.b  singlet  net1 (5' end?)  -  1 
plate01H11.b  singlet 
 
TACO1  1 
plate01H12.b  33 
 
CCDC80  3 
plate02A01.b  singlet 
 
PPIF  1 
plate02A02.b  35 
 
NDUFS2  3 
plate02A03.b  34 
 
FLNA  3 
plate02A04.b  singlet 
 
NUDT21  1 
plate02A05.b  45 
 
COL1A2  6 
plate02A06.b  51 
 
TTN  11 
plate02A07.b  51 
 
TTN  11 
plate02A08.b  22 
 
TBXA2R  2 
plate02A09.b  23 
 
HTRA2  2 
plate02A10.b  45 
 
COL1A2  6 
plate02A11.b  singlet 
 
KIAA0564  1 
plate02A12.b  singlet 
 
SRPX  1 
plate02B01.b  48 
 
CILP  6 
plate02B02.b  44 
 
GSR  4 
plate02B03.b  45 
 
COL1A2  6 
plate02B04.b  singlet 
 
GPS2  1 
plate02B05.b  36 
 
AIP  3 
plate02B06.b  singlet 
 
MYLK  1 
plate02B07.b  24 
 
FBLN2  2 
plate02B08.b  singlet 
 
LAMA4  1 
plate02B09.b  41 
 
PIH1D1  4 
plate02B10.b  25 
 
SMARCB1   2 128 
 
plate02B11.b  26 
 
FLNB  2 
plate02B12.b  singlet 
 
GIN1  1 
plate02C01.b  16 
 
C5orf44   2 
plate02C02.b  singlet 
 
KHDRBS1  1 
plate02C03.b  singlet 
 
AUP1  1 
plate02C04.b  singlet 
 
SH2D4B  1 
plate02C05.b  singlet 
 
AKR7A2  1 
plate02C06.b  27 
 
POSTN  2 
plate02C07.b  singlet 
 
CCNB1  1 
plate02C08.b  48 
 
CILP  6 
plate02C09.b  singlet  zgc:153607 (3' exon?  -  1 
plate02C10.b  singlet  creb3l3l  -  1 
plate02C11.b  singlet 
 
L2HGDH  1 
plate02C12.b  18  hbs1l (with intron?)  HBS1L  2 
plate02D01.b  singlet 
alternate exon of si:dkey-21k10.1 
(PTPRF)?  -  1 
plate02D02.b  35 
 
NDUFS2  3 
plate02D03.b  singlet 
 
ttn  1 
plate02D04.b  5 
 
GRB10   1 
plate02D05.b  singlet 
 
PAPSS2  1 
plate02D06.b  37 
 
SMAD6  3 
plate02D07.b  singlet 
 
TUBGCP6  1 
plate02D08.b  39 
 
CPT1A  3 
plate02D09.b  singlet 
 
BAIAP2  1 
plate02D10.b  singlet 
 
ABCA5  1 
plate02D11.b  singlet 
 
ADCY2  1 
plate02D12.b  51 
 
TTN  11 
plate02E01.b  singlet 
 
GPS1  1 
plate02E02.b  38 
 
LOX  3 
plate02E03.b  49 
 
RNF2  10 
plate02E04.b  singlet  bnip2  -  1 
plate02E05.b  41 
 
PIH1D1  4 
plate02E06.b  singlet 
 
SKP2  1 
plate02E07.b  48 
 
CILP  6 
plate02E08.b  22 
 
TBXA2R  2 
plate02E09.b  45 
 
COL1A2  6 
plate02E10.b  51 
 
TTN  11 
plate02E11.b  47 
 
KRIT1  6 
plate02E12.b  singlet 
 
RYBP  1 
plate02F01.b  49 
 
RNF2  10 
plate02F02.b  singlet  LOC570228 (ARHGEF3)   -  1 
plate02F03.b  24 
 
FBLN2  2 
plate02F04.b  34 
 
FLNA  3 129 
 
plate02F05.b  49 
 
RNF2  10 
plate02F06.b  6 
 
MYBPC3   1 
plate02F07.b  singlet 
 
LGALS3  1 
plate02F08.b  39 
 
CPT1A  3 
plate02F09.b  38 
 
LOX  3 
plate02F10.b  28 
 
CDC20  2 
plate02F11.b  singlet  fb06f03 (hmg-like)  -  1 
plate02F12.b  39 
 
CPT1A  3 
plate02G01.b  51 
 
TTN  11 
plate02G02.b  32 
 
GRB10   3 
plate02G03.b  50 
 
TTN  10 
plate02G04.b  48 
 
CILP  6 
plate02G05.b  49 
 
RNF2  10 
plate02G06.b  27 
 
POSTN  2 
plate02G07.b  46 
 
DHRS4  6 
plate02G08.b  singlet 
 
PPT1  1 
plate02G09.b  singlet  im:7136729 (MS4A4A)  -  1 
plate02G10.b  singlet 
 
CACNA1C  1 
plate02G11.b  29 
 
NID2  2 
plate02G12.b  singlet 
 
POLDIP2  1 
plate02H01.b  7  rfx4 (intron?)  -  1 
plate02H02.b  singlet 
 
ADSSL1  1 
plate02H03.b  50 
 
TTN  10 
plate02H04.b  44 
 
GSR  4 
plate02H05.b  30 
 
KRIT1  2 
plate02H06.b  15 
 
HMCN1   2 
plate02H07.b  51 
 
TTN  11 
plate02H08.b  singlet 
 
CTSK  1 
plate02H09.b  51 
 
TTN  11 
plate02H10.b  8 
 
DHRS4L2   1 
plate02H11.b  30 
 
KRIT1  2 
plate02H12.b  singlet 
 
SMG5  1 
plate03A01.b  47 
 
KRIT1  6 
plate03A02.b  9  ADAM12 (5' UTR?)  -  1 
plate03A03.b  37 
 
SMAD6  3 
plate03A04.b  44 
 
GSR  4 
plate03A05.b  23 
 
HTRA2  2 
plate03A06.b  singlet 
 
GMPS  1 
plate03A07.b  singlet 
 
C16orf13  1 
plate03A08.b  48 
 
CILP  6 
plate03A09.b  singlet 
 
ABCD3  1 
plate03A10.b  singlet 
 
LRRC8A  1 
plate03A11.b  49 
 
RNF2  10 130 
 
plate03A12.b  singlet  -  -  1 
plate03B01.b  21 
 
FLNC  2 
plate03B02.b  28 
 
CDC20  2 
plate03B03.b  19 
 
TTN  2 
plate03B04.b  35 
 
NDUFS2  3 
plate03B05.b  singlet 
 
ACAA2  1 
plate03B06.b  25 
 
SMARCB1   2 
plate03B07.b  singlet  repeat?  -  1 
plate03B08.b  singlet  LOC566883 (similar to KCNB2) 
 
1 
plate03B09.b  36 
 
AIP  3 
plate03B10.b  singlet 
 
WDR37  1 
plate03B11.b  10 
 
GSR  1 
plate03B12.b  47 
 
KRIT1  6 
plate03C01.b  50 
 
TTN  10 
plate03C02.b  singlet 
 
BAT5  1 
plate03C03.b  26 
 
FLNB  2 
plate03C04.b  42 
 
CCDC80  4 
plate03C05.b  singlet  repeat?  -  1 
plate03C06.b  11 
 
KRIT1  1 
plate03C07.b  12 
 
CILP  1 
plate03C08.b  50 
 
TTN  10 
plate03C09.b  49 
 
RNF2  10 
plate03C10.b  13 
 
SMOX  2 
plate03C11.b  50 
 
TTN  10 
plate04A01.b  singlet  -  -  1 
plate04A02.b  40 
 
FLNA  4 
plate04A03.b  singlet 
 
MAPRE3  1 
plate04A04.b  singlet 
 
CCBL2  1 
plate04A05.b  singlet 
 
ALDOC  1 
plate04A06.b  singlet 
 
PTP4A3  1 
plate04A07.b  singlet  -  -  1 
plate04A08.b  singlet 
 
PARK2  1 
plate04A09.b  37 
 
SMAD6  3 
plate04A10.b  49 
 
RNF2  10 
plate04A11.b  singlet  -  -  1 
plate04A12.b  singlet 
 
CDC23  1 
plate04B01.b  singlet  -  -  1 
plate04B02.b  36 
 
AIP  3 
plate04B03.b  singlet  -  -  1 
plate04B04.b  42 
 
CCDC80  4 
plate04B05.b  50 
 
TTN  10 
plate04B06.b  singlet 
 
CSTF1  1 
plate04B07.b  singlet  -  -  1 131 
 
plate04B08.b  singlet  -  -  1 
plate04B09.b  singlet  3' of atp2b4 , 5' of mdm4  -  1 
plate04B10.b  42 
 
CCDC80  4 
plate04B11.b  29 
 
NID2  2 
plate04B12.b  singlet  -  -  1 
plate04C01.b  singlet 
 
TBXA2R  1 
tube001.b  46 
 
DHRS4  6 
tube002.b  46 
 
DHRS4  6 
 
 
 